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 Oxygen is essential to life for all higher organisms.  Hypoxia is a 
condition with low oxygen levels.  Under hypoxic conditions there are limited 
cellular energy resources due to inhibition of oxidative phosphorylation 
dependent ATP synthesis.  Hypoxia activates a variety of complex pathways 
to enable cells to maintain homeostasis and survive low oxygen conditions.  
Non-essential processes such as protein synthesis may be inhibited during 
hypoxia.  Furthermore, cells may respond to hypoxic stress by diminishing 
their proliferative rates through cell cycle arrest.   
 
The mechanistic target of rapamycin complex 1 (mTORC1) is a key 
regulator of cell growth and proliferation in response to various upstream 
signals.  Hypoxia has been shown to exert a strong inhibitory effect on 
mTORC1 activity.  Various mechanisms involving gene transcription have 
been proposed to mediate the effect of hypoxia on mTORC1 activity.  In this 
study, I showed that oxygen concentrations regulate mTORC1 activity in a 
highly dynamic manner.  The rapid response of mTORC1 to changes in 
oxygen concentrations was not mediated by the HIF transcription factor or its 
transcriptional targets, REDD1 and BNIP3.  Interestingly, I observed that the 
rapid response of mTORC1 activity to changes in oxygen concentrations is 
independent of transcription and new protein synthesis.  This suggests a post-
translational regulation mTORC1 activity in hypoxia and reoxygenation.  My 
results also suggest that hypoxia does not regulate mTORC1 via the TSC1/2 or 
Ragulator pathways but directly at the level of mTORC1.  In conclusion, my 






concentrations via a post-translational mechanism that may involve a heme 
containing protein.     
 
REDD1 is a negative regulator of mTORC1 that is known to be 
transcriptionally upregulated in hypoxia.  During hypoxic stress, REDD1 has 
been reported to play an important role as a mediator of mTORC1 inhibition.  
REDD1 is also subject to highly dynamic transcriptional regulation in 
response to a variety of other stress signals.  In addition, the REDD1 protein is 
highly unstable.  However, it is currently not well understood how REDD1 
protein stability is regulated.  In this study, I discovered that mTORC1 
regulates REDD1 protein stability in a 26S proteasome dependent manner.  
Inhibition of mTORC1 resulted in reduced REDD1 protein stability and a 
consequent decrease in REDD1 expression.  Conversely, activation of the 
mTORC1 pathway increases REDD1 protein levels.  I show that REDD1 
degradation is not regulated by HUWE1, Cul4a or other Cullin E3 ubiquitin 
ligases.  My study shows that mTORC1 increases REDD1 protein stability and 
reveals a novel mTORC1-REDD1 feedback loop.  This feedback mechanism 
may limit the inhibitory action of REDD1 on mTORC1. 
 
CDC6 is an important component of the pre-replication complex and 
plays an essential role in the regulation of DNA replication in eukaryotic cells. 
Deregulation of CDC6 protein levels results in rereplication and genomic 
instability.  CDC6 expression is tightly regulated during the cell cycle.  It is 
known that hypoxia can lead to cell cycle changes.  Furthermore, it has been 
reported that hypoxia affects CDC6 protein levels.  Therefore, I hypothesized 






arrest.  However, in my studies I did not observe any significant changes in 
CDC6 protein levels at low oxygen concentrations.  Hence, in my further 
studies I focused on the post-translational regulation of CDC6 in normoxic 
conditions.  One major mechanism of cell cycle dependent regulation of 
CDC6 is APC
Cdh1
 mediated protein ubiquitination and degradation during G1 
phase.  In addition to APC
Cdh1
 dependent degradation, alternative, Cullin 
RING E3 ubiquitin ligase dependent degradation pathways have been 
characterized in yeast.  In this project, I studied whether Cullin RING E3 
ligases also play a role in the turnover of CDC6 protein in mammalian cells.  
To this end, I used the Nedd8 E1 inhibitor MLN4924, which blocks the 
activity of all Cullin E3 ligases.  I observed that treatment with MLN4924 
increased CDC6 protein expression.  However, this effect was due to a delay 
in cell cycle progression from G1 to S phase, resulting in accumulation of cells 
with high CDC6 protein levels.  Therefore, my results indicate that unlike in 
lower eukaryotes, Cullin E3 ligases are not involved in the basal turnover of 
CDC6 in mammalian cells.   
 
Interestingly, I also found that the DNA cross-linker mitomycin C 
induces marked CDC6 protein degradation.  Of note, mitomycin C requires 
bioreduction for activation and has hence been demonstrated to have greater 
cellular effects under hypoxic conditions.  I found that mitomycin C induced 
CDC6 degradation is not mediated by APC
Cdh1
, Cullin or HUWE1 E3 
ubiquitin ligases.  Notably, mitomycin C mediated CDC6 degradation requires 
the neddylation pathway.  My results provide evidence for a novel, cullin 
independent mechanism of CDC6 posttranslational regulation upon DNA 
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1.0 Characterization of the cellular signaling and response to hypoxia  
 
Hypoxia is a condition with oxygen levels lower than the physiological 
oxygen concentrations (approximately 7%).  Hypoxic stress occurs when 
there is diminished supply of oxygen to tissues or there is an increase in 
oxygen demand.  To adapt to hypoxia, cells respond by reducing fundamental 
physiological activities such as protein translation and energy metabolism, 
increasing protein degradation as well as inducing cell cycle arrest to 
maintain homeostasis and enable cells to survive low oxygen conditions.  The 
mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway, an 
important regulator of protein synthesis, is rapidly inhibited upon reduced 
oxygen availability to conserve energy levels in cells.  This is because protein 
synthesis is a high-energy process and in hypoxia, ATP levels are severely 
decreased in cells.  Hence, inhibition of the mTORC1 signaling pathway in 
hypoxia and thereby downregulating protein synthesis would allow cells to 
utilize available energy for more essential survival mechanisms.   
 
The mTORC1 pathway is activated through the inhibition of tuberous 
sclerosis complex -1 and -2 (TSC1/2) via phosphorylation by different 
upstream kinases of multiple signaling pathways including PI3K/Akt, 
MEK/ERK/RSK and MAPK/MK2 (Manning et al., 2002; Inoki et al., 2002; Li 
et al., 2003; Ma et al., 2005).  Inactivation of GTPase activator TSC1/2 leads 
to the accumulation of the active GTP bound form of Rheb.  GTP-Rheb binds 
to and activates mTORC1 (Figure 1).  Recently, it has also been shown that in 




Ragulator complex through its translocation to the lysosomal surface where 
mTORC1 is activated by Rheb (Sancak et al., 2010).   
Figure 1. The mTORC1 pathway. mTORC1 is a sensor of various stress 
signals and the mTORC1 pathway regulates translation via phosphorylation of 
its downstream targets eEF2K, p70S6K and 4E-BP1.  
 
Activated mTORC1 stimulates protein synthesis and cell growth 
through phosphorylation of its downstream targets: ribosomal S6 kinase 1 
(p70S6K), eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) 
and eukaryotic elongation factor 2 kinase (eEF2K) (Browne and Proud, 2004; 





through phosphorylation and activation of its target ribosomal protein S6, a 
component of the 40S ribosomal subunit.  4E-BP1 is a translational repressor 
protein that is normally bound to eIF4E to inactivate the binding of eIF4E to 
the 5’ cap of mRNAs to initiate translation (Gingras, Raught and Sonenberg, 
1999).  Hyperphosphorylation of 4E-BP1 by mTORC1 prevents binding of 
4E-BP1 to eIF4E and thereby promotes translation.  On the other hand, eEF2K 
mediates the translocation step of elongation through its phosphorylation and 
inactivation of eEF2, the protein which controls ribosomal translocation 
during elongation of the new polypeptide chain (Browne and Proud, 2002).   
 
A further mechanism important in the hypoxic response is protein 
ubiquitination, which plays a critical role as it allows cells to respond quickly 
to changes in the environment.  The most well studied ubiquitination event in 
hypoxia is the regulation of the transcription factor, Hypoxia-Inducible Factor 
1 (HIF-1) (Epstein et al., 2001; Bruick, 2001; Bruick and McKnight, 2001).  
HIF-1 proteins exist in 2 subunits: the oxygen sensitive HIF-1 subunit and 
the constitutively expressed nuclear subunit, HIF-1.  The expression of the 
HIF-1 subunit is a highly specific response to hypoxia (Huang et al., 1996).  
Although HIF-1 mRNA is constitutively expressed in cells, the HIF-1 
protein is rapidly degraded in normoxia by the ubiquitin-proteasome pathway 
via Cullin 2 E3 ubiquitin ligases (Huang et al., 1998; Salceda and Caro, 1997; 
Maxwell et al., 1999; Cockman et al., 2000; Kamura et al., 2000; Tanimoto et 
al., 2000).  This degradation process is inhibited in hypoxia to allow rapid 
accumulation of HIF-1 levels in cells followed by nuclear translocation of 




2000; Kallio et al., 1998) (Figure 2).  The HIF-1 transcription factor is known 
to regulate genes important for survival in hypoxia including genes involved 
in angiogenesis such as vascular endothelial growth factor (VEGF) (Forsythe 
et al., 1996) as well as in glycolysis, for instance GLUT1 (Ebert, Firth and 
Ratcliffe, 1995), signifying its importance in hypoxia.  
  
Figure 2. Regulation of HIF-1 protein stability in normoxia and hypoxia.  In 
nomoxia, HIF1 is hydroxylated by prolyl hydroxylases and continuously 
degraded by Cullin 2 VHL E3 Ligase.  In hypoxia, prolyl hydroxylases are 
inactive leading to the stabilization of HIF1 which then translocate into the 
nucleus to dimerize with HIF1 for the transcription of hypoxia response 
genes. 
 
 Although HIF-1 has always been thought to function as the key 
regulator in hypoxia, other HIF-1 independent mechanisms also play an 
important in cellular adaptation to changes in oxygen concentrations.  





In both cases, cells grow rapidly resulting in a hypoxic environment at the 
inner region of the growing cell mass.  It has been reported that the 
expression of FBXl14 is potently downregulated in hypoxia, thereby leading 
to increased levels of its substrate, SNAIL1 (Vinas-Castells et al., 2010).  
SNAIL1 is a transcription factor which plays a fundamental role in initiating 
epithelial-mesenchymal transition (EMT), a phenotype that is induced in 
hypoxia.  
 
Also, cell cycle checkpoints are activated in hypoxia to suppress cell 
proliferation and enable cells to adapt to and survive in hypoxia (Amellem et 
al., 1998).  Diminished oxygen levels lead to the activation of the cell cycle 
checkpoint at the G1/S phase (Amellem et al., 1998; Schmaltz et al., 1998).  
An essential step in the transition of the G1/S phase is the phosphorylation of 
the retinoblastoma protein (Rb) by specific cyclin-dependent kinase (CDK)-
cyclin complexes.  This leads to the inactivation of the growth suppressive 
function of Rb (Blagosklonny and Pardee, 2000; Planas-Silva and Weinberg, 
1997).  However, in hypoxia, CDK2 activity is diminished, resulting in the 
hypophosphorylation and thereby activation of Rb to induce G1 cell cycle 
arrest (Amellem et al., 1998; Krtolica, Krucher and Ludlow, 1999). 
 
 Various mechanisms are activated in cells in response to hypoxic stress 
to enable cells to adapt to a changing environment and ensure cell survival.  
Cellular response to hypoxic stress is complicated as it occurs at many 
different levels and the different mechanisms be can interdependent in their 




characterize different mechanisms activated in hypoxia and my work is 
divided into three parts.  In the first part I studied how oxygen levels regulate 
the mTORC1 pathway in hypoxia and upon reoxygenation.  In the second, I 
studied how the stability of REDD1 is regulated.   The REDD1 protein is a 
negative regulator of the mTORC1 pathway.  REDD1 is normally 
upregulated in hypoxia and degraded upon reoxygenation.  Finally, in the last 
part, I studied how the protein CDC6, an important protein of the pre-
replication complex, is degraded.  CDC6 has been reported to be 
downregulated in hypoxia.  I therefore hypothesized that oxygen levels may 
regulate CDC6 protein stability and consequently, downregulation of CDC6 
protein levels may contribute to cell cycle arrest in hypoxia.  It is therefore 
important to understand how this protein is degraded.  However, I observed 
that CDC6 levels in cells exposed to hypoxic conditions were not 
significantly lower compared to cells in normoxia.  Therefore, the focus of the 
last part of the project was to characterize the hypoxia-independent regulation 







2.0 Materials and methods 
 
2.1 Cell culture and transfection  
Human embryonic kidney (HEK293) (ATCC and Invitrogen), mammary 
carcinoma (MCF7) (ATCC), Mouse Embryonic Fibroblasts (MEF), Hela cells, 
renal cell carcinoma (RCC) 786-O cells (Iliopoulos et al., 1995; Lonergan et 








  MEF cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM).  Colon carcinoma (HCT116) 
cells (ATCC) were cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium.  Both media were supplemented with 10 % inactivated fetal bovine 
serum, 2 mM L-glutamine and 1 % penicillin-streptomcin (Invitrogen) and all 
cell lines were incubated at 37 °C with 5 % CO2.  RCC 786-O VHL null and 
HA-pVHL (WT) reconstituted 786-O cells were kindly provided by Michael 









 MEFs were kindly provided by D.J. 
Kwiatkowski (Brigham and Women’s Hospital, Harvard Medical School, 
Boston, MA) (Zhang et al., 2003).  For overexpression experiments, sub-
confluent cells were transfected using Genejuice (Novagen) according to the 
manufacturer's instructions.  Knockdown experiments using siRNAs 
(predesigned dsiRNAs, IDT) were performed using Lipofectamine RNAiMax 








2.2 Plasmid constructs  
The human BNIP3-V5 pcDNA3 plasmid was constructed by PCR 
amplification from the cDNA purchased from Mammalian Gene Collection 
and inserted into the pcDNA3 vector with a C terminal V5 tag using KpnI and 
XbaI restriction sites with a SacII restriction site inserted between BNIP3 and 
the V5 tag.  HIF-1 P402A/P564A-V5 pcDNA3 plasmid was constructed as 
described previously (Hagen et al., 2003).  The HSPBAP1-V5 plasmid was 
PCR amplified from HEK293 cDNA and ligated in to the pCDNA3 vector 
with a C terminal V5 tag using the same restrictions sites as BNIP3-V5 
pcDNA3 construct. 
 
For the REDD1-V5 pcDNA3 plasmid, REDD1 gene was first PCR amplified 
from human brain cDNA and subsequently ligated into the pcDNA3 backbone 
with a C terminal V5 tag using the same restriction sites as the BNIP3-V5 
pcDNA3 construct.  REDD2-V5 pcDNA3 was also constructed in the same 
way.  Mutagenesis of REDD1 Threonines 23 and 25 to Alanines or Aspartate 
was carried out using the Stratagene site-directed mutagenesis kit.  Mutation 
of different combinations of REDD1 lysine residues to alanines was 
performed using the Stratagene site-directed mutagenesis kit.  Construction of 
REDD1 truncation mutants i.e. C-terminal end truncation mutants (1-132), (1-
162), (1-202) and N-terminal end truncation mutant (129-233) were carried 
out using PCR with the appropriate primers. 
 
The following plasmids were purchased from Addgene: FLAG-TSC2 




FLAG (Addgene Plasmid 21334) (Peterson et al., 2009), pBabe GFP Small T 
Antigen (Addgene Plasmid 10673) (Boehm et al., 2005), pRK5 HA Raptor 
(Addgene Plasmid 8513) (Kim et al., 2002), FLAG-Rheb pcDNA3 (Addgene 
Plasmid 19996) (Urano et al., 2007).  The FLAG-Rheb S16H pcDNA3 mutant 
was constructed from the wild type Flag-Rheb pcDNA3 by mutation of Serine 
to Histidine using Stratagene site-directed mutagenesis kit.   
 
The human IDH1 wt-V5 pcDNA3 plasmid was constructed by PCR 
amplification from the cDNA Purchased from Mammalian Gene Collection 
(MGC clone 3889331) and inserted into the pcDNA3 vector with a C terminal 
V5 tag KpnI and SacII.  The IDH1 R132H-HA pcDNA3 plasmid was 
constructed by mutation of Arginine to Histidine using the Stratagene site-
directed mutagenesis kit. 
 
The human PRMT1-V5 pcDNA3 plasmid was constructed by PCR 
amplification from HEK293 cDNA.  The amplified PRMT1 was inserted into 
the pCDNA3 vector with a C-terminal V5 tag using the same restriction sites 
as the BNIP3-V5 pcDNA3 construct. The human Siah2-FLAG pcDNA3 was 
PCR amplified from HEK293 cDNA and inserted into the pCDNA3 vector 
with a C-terminal FLAG tag.  
 
The human CDC6 pcDNA3 plasmid was constructed by PCR amplification 
from the cDNA purchased from Mammalian Gene Collection.  The amplified 
CDC6 coding sequence was inserted into the pcDNA3 vector with a C 




ΔD & KEN box mutant was constructed by deleting amino acids 56-83 
containing D box and KEN box from full length CDC6-V5 pcDNA3 plasmid.   
 
The S6 kinase plasmids HA-p70S6K1 T389D pcDNA3 and HA-p70S6K1 
T389A pcDNA3 were constructed from the pRK7-HA-S6K1-WT (Addgene 
Plasmid 8984) (Schalm and Blenis, 2002). The HA-p70S6K1 gene was 
digested from the pRK7-HA-S6K1-WT plasmid using XbaI and EcoRI 
restriction enzymes and ligated in to the pcDNA3.1 (-).  Mutagenesis of 
p70S6K1 Threonine 289 site to Alanine or aspartate was carried out using the 
Stratagene site-directed mutagenesis kit.  GSK3β and FRAT1 plasmid was 
previously described (Hagen et al., 2002).   
 
The 3 kb REDD1 promoter pGL-3 basic or 0.6 kb REDD1promoter pGL-3 
basic constructs were kindly provided by Leif W. Ellisen (Harvard Medical 
School) (Ellisen et al., 2002).   
 
The dnCul1-V5 pcDNA3 (amino acids 1-452), dnCul3-V5 pcDNA3 (amino 
acids 1-427) and dnCul4a-V5 pcDNA3 (amino acids 1-439) plasmids were 
described previously.  The dnCul4b-FLAG pcDNA3 (amino acids 1-594) 
plasmid was from Addgene (Plasmid 15822) (Jin et al., 2005).  The 
tetracycline-inducible dnUbc12 (C111S), dnCul1-V5 (amino acids 1-452) and 
dnCul4a (amino acids 1 to 439) cell lines were generated using the T-Rex 
system (Invitrogen) according to the manufacturer’s instructions, as previously 





2.3 Oxygen conditions  
Hypoxic condition (1 % O2, 5 % CO2 and balanced with N2) was achieved in a 
Pro-ox 110 oxygen controller and Pro-ox in vitro chamber (BioSpherix) or an 
Invivo2 400 hypoxia workstation (Ruskinn Technology).  For reoxygenation 
experiments, cells were first treated with the indicated compounds or 
transfected before hypoxia incubation, followed by removal from hypoxic 
chamber and exposure to atmospheric oxygen for reoxygenation. 
 
2.4 Immunoblotting  
Whole cell lysates were prepared by rinsing the cells in ice cold 1x PBS 
followed by cell lysis using triton-X lysis buffer with the following 
composition: 25 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2.5 mM EDTA, 2.5 
mM EGTA, 20 mM NaF, 1 mM Na3VO4, 20 mM sodium β-glycerophosphate, 
10 mM sodium pyrophosphate, and 0.5 % Triton X-100 containing freshly 
added protease inhibitor cocktail (Roche Diagnostics) and 0.1 % β-
mercaptoethanol.  Equal amounts of protein from each sample were separated 
by SDS–PAGE (10%) and transferred onto nitrocellulose membranes. The 
blots were probed with a primary antibody followed by a secondary antibody 
conjugated to horseradish peroxidase. The following primary antibodies were 
used: rabbit anti-phospho-p70 S6 kinase (Thr389) (9234; Cell Signaling), 
rabbit anti-p70 S6 kinase (9202; Cell Signaling), rabbit anti-REDD1 (10638-1-
AP; Proteintech), mouse anti-HIF-1a (610959; BD Biosciences), mouse anti-a-
tubulin (236–10501; Molecular Probes, Invitrogen) and mouse anti-V5 
(MCA1360; AbD Serotec), mouse anti-p27 (610241; BD Biosciences), mouse 




(610202; BD Transduction Laboratories), mouse anti-Mcl-1 (sc-12756; Santa 
Cruz Biotechnology), mouse anti-Cdc6 (sc-9964; Santa Cruz Biotechnology), 
anti-p21 (F-5) (sc6246; Santa Cruz Biotechnology), mouse anti-Cdh1 
(DCS266), mouse anti-SLBP (H00007884-M01; Abnova), mouse anti-MDM2 
(Santa Cruz Biotechnology), mouse anti-FLAG M2 (F-3165; Sigma), rat anti-
HA (clone 3F10) (Roche Applied Science).  Protein levels on the blots were 
detected using the enhanced chemiluminescence system (GE Healthcare) 
according to the manufacturer’s instructions.  Western blots shown are 
representative of at least two independent experiments. 
 
2.5 Immunoprecipitation 
10 μl of anti-FLAG M2 agarose (Sigma) or 1.5 μl of V5 antibody, coupled to 
10 μl of protein G-sepharose (Amersham Biosciences) was used for 
immunoprecipitations. 500 μl pre-cleared lysate from HEK293 cells 
transfected in 60 mm tissue culture plates was added. The samples were 
tumbled at 4 °C for 1 h and the agarose or sepharose beads were then washed 
four times in 1 ml of cold buffer containing 20 mM Tris (pH 7.5), 0.6 M NaCl 
and 1 mM EGTA and once in buffer containing 50 mM Tris (pH 7.5). The 
immunoprecipitated proteins were then denatured in SDS-sample buffer and 
subjected to SDS-PAGE and Western blotting.  
 
2.6 In vitro ubiquitination assay 
Pre-cleared lysate from HEK293 cells transfected with 2 g REDD1-V5 in 
two 60 mm plates was added to protein G-sepharose beads coupled with V5 




then washed four times in 1 ml of cold Nonidet P-40 buffer containing 50 mM 
Tris-HCl pH 7.5, 0.5 % NP-40, 5 % glycerol, 0.5 mM EDTA and 50 mM 
NaCl.  Pre-cleared lysates from untransfected HEK293 cells in 100 mm plates 
were added to the REDD1-V5 samples bound to sepharose beads.  Next, 10 l 
of ubiquitination system (Boston Biochem Cat # K-960) containing 25 mM 
Hepes, 20 nM MgCl2, 10 nM E1 ubiquitin enzyme, 0.1 M E2 ubiquitin 
enzyme, 50 M ubiquitin and 0.5 M ATP was added followed by shaking 
incubation at 30 °C for 1 h.  After that, the samples were washed twice using 
cold 1 X PBS.   
 
2.7 Luciferase reporter assay 
HEK293 cells at approximately 70% confluence were transfected with 0.2 μg 
firefly luciferase pGL-3 basic reporter plasmids (driven by REDD1 promoters) 
using GeneJuice according to the manufacturer’s instructions. Firefly 
luciferase activity was measured after 48 hours using the Steady-Glo reporter 
assay system (Promega). 
 
2.8 iTRAQ analysis 
HEK293T cells stably expressing REDD1-FLAG puroMARX or EGFP 
puroMARX were grown in 100 mm tissue culture plates.  MG-132 (20 μM) 
was added to cells for 6 hours followed by cell lysis with triton-X lysis buffer 
(described above) or hypotonic lysis buffer (1M Tris-HCl pH 7.5, 0.5 M 
EDTA, 100 mM EGTA, 20 mM NaF, 1 mM Na3VO4, 20 mM sodium β-
glycerophosphate and 10 mM sodium pyrophosphate containing freshly added 




cells were tumbled at 4 °C for 1 h with 20 μl of anti-FLAG M2 agarose 
(Sigma) beads and washed four times in 1 ml of cold Nonidet P-40 buffer.  
Washed samples were eluted from FLAG beads by adding 0.1 M acetic acid 
and incubated at room temperature by gently shaking for 5 mins.  The 
supernatant was transferred to fresh tubes containing 5 l neutralizing buffer 
(1N NaOH).  The samples were shipped on dry ice to the UVic Genome BC 
Proteomics Centre for iTRAQ analysis.   
 
2.9 In vitro phosphorylation of REDD1 and FRAT1 
FLAG-immunoprecipates (REDD1-FLAG or FRAT-FLAG) from HEK293 
cell lysates were incubated on a shaking platform for 45 minutes at room 
temperature in 50 mM Tris pH7.5, 25 mM MgCl2 and 2 mM DTT in the 
presence or absence of 1 mM ATP and/or the recombinant protein GSK3β.  
Following the reaction, the samples were denatured in SDS-sample buffer and 
subjected to SDS-PAGE and immunoblotting. 
 
2.10 Cell synchronization and cell cycle analysis 
HeLa cells synchronized at G2/M phase by blocking with thymidine (2 mM) 
for 20 hours, washed and released in complete medium for 4 hours , followed 
by incubation in nocodazole (100 ng/ml) for 13 hours.  Mitotic cells were 
plated in 6 well plates (2 X 10
6
 cells) in the presence or absence of MLN4924 
(1 μM) and collected every 3 hours for 12 hours and at 24 hours.  For cell 
cycle analysis, Hela cells were fixed with 70 % ethanol on ice for at least 2 
hours and stained in propidium iodide (20 μg/ml) and RNase A (0.1 μg/ml).  




cytometer (Beckman Coulter) and the data were analyzed using Dako Summit 
v4.3.    
3.0 Post-translational Regulation of mTOR Complex 1 in Hypoxia and 
Reoxygenation 
 
3.1 Introduction  
 
 The mechanistic target of rapamycin complex 1 (mTORC1) functions 
as a key regulator of cell growth and proliferation by acting as a sensor of 
various types of stress signals.  Under conditions of stress unfavorable for cell 
growth, the mTORC1 pathway is inhibited.  One important negative regulator 
of the mTORC1 activity is hypoxia (Arsham, Howell and Simon, 2003).  
Under hypoxic conditions there are limited cellular energy resources due to 
inhibition of oxidative phosphorylation dependent ATP synthesis.  Hence, 
hypoxia mediated mTORC1 inhibition is of great physiological significance as 
it downregulates non-essential cellular reactions and pathways in favor of 
processes that are critical for cell viability.   
 
  mTORC1 is a complex consisting of mTOR, a serine/threonine kinase, 
in association with the regulatory associated protein of mTOR (Raptor) (Hara 
K et al., 2002), proline-rich Akt substrate 40 (PRAS40) (Wang et al., 2007; 
Haar et al., 2007) and G-protein -subunit-like protein/mLST8 (Kim et al., 
2003).  The mTORC1 kinase stimulates protein synthesis and cell growth 
through phosphorylation of its downstream targets: ribosomal S6 kinase 1 




eukaryotic elongation factor 2 kinase (eEF2K) (Browne and Proud, 2004; 
Fingar et al., 2002).  mTORC1 is activated via two signaling pathways, 
depending on its upstream signals.  Both pathways activate mTORC1 through 
binding of the small GTPase Rheb.  The first pathway is dependent on the 
presence of growth factors. Growth factor dependent activation of cellular 
signaling leads to the inhibition of an important negative upstream regulator of 
the mTORC1 pathway, the tuberous sclerosis complex -1 and -2 (TSC1/2) 
complex.  This complex normally functions as a GTPase to convert the active 
GTP-Rheb into the inactive GDP bound form.  Under nutrient- and energy-
replete conditions different upstream kinases of multiple signaling pathways 
including PI3K/Akt, MEK/ERK/RSK and MAPK/MK2 (Manning et al., 2002; 
Inoki et al., 2002; Li et al., 2003; Ma et al., 2005) phosphorylate and inhibit 
the TSC1/2 complex, thus leading to mTORC1 activation.  In the second 
pathway, presence of amino acids leads to the Rag-GTPases-Ragulator 
dependent translocation of mTORC1 to the lysosomal surface, where 
mTORC1 is activated by Rheb (Sancak et al., 2010).   
 
 Hypoxia has been reported to inhibit mTORC1 via different 
mechanisms (Figure 3).  For instance, it has been reported that inhibition of 
mTORC1 in hypoxia is a consequence of activation of AMP-activated protein 
kinase (AMPK) (Hardie and Hawley, 2001).  Low oxygen concentrations 
block mitochondrial ATP production leading to decreased ATP levels and 
subsequently, activation of AMPK.  AMPK has been reported to activate 
TSC1/2, leading to inhibition of mTORC1 (Liu et al., 2006).  In addition, 




Development and DNA damage responses 1), which is a known target gene of 
the transcription factor Hypoxia Inducible Factor-1 (HIF-1) (Reiling and 
Hafen, 2004; Brugarolas et al., 2004).  HIF-1 is stabilized in hypoxia through 
inhibition of oxygen-dependent prolyl hydroxylases (PHDs) (Bruick, 2001); 
(Epstein et al., 2001) or activation of ataxia telangieactasia mutated (ATM) 
(Cam et al., 2010).  On the other hand, mTORC1 inhibition in hypoxia has 
also been shown to be regulated through the inactivation of Rheb by BNIP3 
(Bcl2/adnovirus E1B 19 kDA protein-interacting protein 3) (Li et al., 2007).  
Similar to REDD1, BNIP3 is also transcriptionally induced in hypoxia via the 
HIF transcription factor.  Finally, the promyelocytic leukemia (PML) protein 
was reported to inhibit Rheb-mTORC1 association and to promote the nuclear 
accumulation of mTOR, where Rheb is absent, thus preventing mTORC1 
activation (Bernardi et al., 2006). 
 
However, studies have shown that mTORC1 inhibition in hypoxia can 
occur independently of AMPK, HIF-1 and REDD1, suggesting the existence 
of additional mechanisms (Arsham, Howell and Simon, 2003).  Furthermore, 
the dynamics with which mTORC1 responds to changing oxygen 
concentrations are currently not well characterized.  In this study, I found that 
the inhibition of mTORC1 is rapidly reversed upon reoxygenation, suggesting 
a highly dynamic oxygen dependent regulation of mTORC1 activity via post-
translational mechanisms.  I also found that previously reported mTORC1 
inhibitory factors do not play a major role in the rapid mTORC1 regulation in 
hypoxia and reoxygenation.  My results suggest that a heme containing protein 






Figure 3. Regulation of mTORC1 pathway in hypoxia.  The mTORC1 









3.2 Results  
3.2.1 mTORC1 is inhibited in hypoxia and rapidly reactivated upon 
reoxygenation 
 
To test for mTORC1 activity in hypoxia and reoxygenation, I 
incubated cells in a hypoxic chamber at 1 % oxygen for 4 hours followed by 
reoxygenation at 21 % oxygen and cell lysis at different time points.  
mTORC1 activity was markedly reduced in all cell types, as detected by the 
phosphorylation status of the mTORC1 target p70 S6 kinase (p70S6K) (Figure 
4), when cells were placed in hypoxia.  This is consistent with previous reports 
that hypoxia inhibits mTORC1 activity (Arsham, Howell and Simon, 2003).  
Interestingly, upon reoxygenation, there was a rapid reactivation of mTORC1 
activity, as shown by the quick accumulation of phosphorylated p70S6K 
(Figure 4).  The effect of reoxygenation on p70S6K phosphorylation is 
mTORC1 dependent as it is completely prevented in the presence of the 
specific mTORC1 inhibitor rapamycin (Figure 5).  To investigate the 
mechanism through which hypoxia regulates mTORC1, I initially studied the 











Figure 4. mTORC1 is inhibited in hypoxia and rapidly reactivated upon 
reoxygenation.   HEK293, MCF7, HCT116 and MEF cells were incubated at 
21 % or 1 % O2 for 4 hours, followed by reoxygenation in normoxia and cell 
lysis at the indicated time points.  Hypoxia (1% O2) inhibits mTORC1 activity 
as indicated by the marked reduction in p70 S6 kinase (p70S6K) T389 
phosphorylation compared to normoxia (21% O2).  Upon reoxygenation, 










Figure 5. mTORC1 activity in hypoxia and reoxygenation is mTORC1 
dependent.  HEK293 cells were pre-treated with 20 nM rapamycin prior to 
hypoxic incubation for 4 hours at 1 % O2, followed by reoxygenation and cell 
lysis at 0, 5 and 15 min.  
 
3.2.2 BNIP3 and REDD1 are partially responsible for mTORC1 
inhibition in hypoxia   
 
BNIP3 is strongly induced in hypoxia and has been shown to mediate 
mTORC1 inhibition in hypoxia.  BNIP3 binds to Rheb and consequently 
prevents activation of mTORC1 (Li et al., 2007).  To determine the effect of 
BNIP3 on mTORC1 activity, I overexpressed control vector or BNIP3-V5 
pcDNA3 in HEK293 cells and determined the phosphorylation status of 
p70S6K in normoxia and hypoxia.  I observed that BNIP3 overexpression did 
not result in any difference in mTORC1 activity compared to control cells 
under both nomoxic and hypoxic conditions (Figure 6) indicating that BNIP3 
did not induce mTORC1 inhibition.  I also used siRNA to silence BNIP3 
expression.  Efficiency of the siRNAs used to knock down BNIP3 was 
confirmed in a separate experiment (Figure 7A).  I observed that silencing of 
BNIP3 using siRNAs resulted in only a slight increase in mTORC1 activity in 
hypoxia compared to controls (Figure 7B).  Taken together, my results suggest 















Figure 6. BNIP3 overexpression has no effect on mTORC1 activity.  HEK293 
cells were transfected with 0.4 μg pcDNA3 vector control or BNIP3-V5 






Figure 7.  BNIP3 is 
partially responsible for 
mTORC1 inhibition in 
hypoxia.  (A) HEK293 
cells were transfected 
with 20 nM control or 
BNIP3 siRNAs 16 hours 
after the cells were 
transfected with 0.15 μg 
BNIP3-V5 pcDNA3 to 
determine siRNA 
efficiency.   
 
(B) HEK293 cells were 
transfected with 20 nM 
control or BNIP3 
siRNAs for 3 days 
followed by hypoxia 
incubation for 4 hours at 





The transcriptional target of HIF-1α, REDD1, has been reported to 
negatively regulate mTORC1 in a TSC1/2 dependent manner (Reiling and 
Hafen, 2004; Brugarolas et al., 2004) and may mediate the inhibitory effect of 
hypoxia on mTORC1 activity.  I found that REDD1 overexpression did not 
result in the inhibition of mTORC1 activity in normoxia as expected but 
instead caused a slight increase in p70S6K phosphorylation (Figure 8).  In 
hypoxia, REDD1 overexpression also did not result in marked reduction in the 
phosphorylation of p70S6K compared to control cells (Figure 8).  Similarly, 
overexpression of the REDD1 ortholog, REDD2, did not affect mTORC1 
activity in normoxia and hypoxia (Figure 9).  This result suggests that 
increasing the cellular REDD1/REDD2 levels does not result in mTORC1 
inhibition.  To test whether endogenous levels of REDD1 and REDD2 play a 
role in regulating mTORC1 activity in hypoxia, I knocked-down both 
isoforms using siRNAs.  Combined knockdown of REDD1 and REDD2 in 
HEK293 cells only partially reversed hypoxia dependent inhibition of 





























Figure 8.  REDD1 is partially responsible for mTORC1 inhibition in hypoxia.  
HEK293 cells were transfected with 0.4 μg pcDNA3 vector control or 
REDD1-V5 pcDNA3 for 3 days followed by hypoxia incubation for 4 hours at 





Figure 9.  REDD2 does not 
regulate mTORC1 activity.  
HEK293 cells were transfected 
with 0.4 μg pcDNA3 vector 
control or REDD2-V5 pcDNA3 
for 3 days followed by hypoxia 
incubation for 4 hours at 1 % O2 

























Figure 10.  REDD1 and REDD2 
are partially responsible for 
mTORC1 inhibition in hypoxia.  
HEK293 cells were transfected 
with 20 nM control or REDD1 
and REDD2 siRNAs for 3 days 
and incubated in hypoxia for 4 




To test the possibility that the reactivation of mTORC1 upon 
reoxygenation is related to REDD1, I determined the hypoxia induced changes 
in REDD1 protein expression in a number of cell lines.  In MCF7, HEK293 
and MEF cells, REDD1 expression was upregulated in hypoxia and 
downregulated upon reoxygenation (Figure 4).  However, the downregulation 
of REDD1 levels occurred at a much slower rate compared to the rapid 
reactivation of mTORC1 upon reoxygenation (Figure 4).  This suggests that 
the rapid mTORC1 reactivation upon reoxygenation is independent of REDD1.  
Furthermore, it was observed that in HCT116 cells REDD1 expression in 
hypoxia and reoxygenation showed the opposite trend compared to MCF7 and 
HEK293 cells.  Thus, REDD1 expression was downregulated in hypoxia and 
upregulated upon reoxygenation (Figure 4).  However, as mentioned above, 
hypoxia and reoxygenation had comparable effect on mTORC1 activities in all 
cell lines.  Taken together, these results strongly suggest REDD1 does not play 






3.2.3 HIF-1 is not involved in mTORC1 regulation in hypoxia and 
reoxygenation  
 
The transcription factor, Hypoxia-Induced Factor 1 (HIF-1) is a key 
mediator of the cellular response to oxygen deprivation and both BNIP3 and 
REDD1 are transcriptional targets of HIF-1.  I therefore investigated the role 
of HIF-1α in mTORC1 regulation.  HIF-1 comprises of a constitutively 
expressed HIF-1 subunit and an oxygen regulated HIF-1 subunit (or the 
HIF-2α or HIF-3α isoforms).  Under normoxic conditions, HIF-1 is 
hydroxylated on conserved proline residues at positions 402 and 564 by 
oxygen dependent PHDs (Epstein et al., 2001; Bruick, 2001), thus leading to 
von Hippel-Lindau (VHL) protein dependent ubiquitination and proteasomal 
degradation (Ivan et al., 2001; Jaakkola et al., 2001; Masson et al., 2001).  In 
hypoxia, PHDs are suppressed and the HIF-1 protein is stabilized, resulting 














Figure 11.  Regulation of HIF-1α stability in normoxia and hypoxia.  DFO 
and DMOG act as hypoxia mimics to inhibit prolyl hydroxylases and thereby 
leading to the stabilization of HIF1.  DFO is an iron chelator and DMOG is a 
2-oxoglutarate analog. 
 
To test the involvement of HIF-1α, I used a mutant in which the two 
proline residues are substituted with alanine resulting in a stable HIF-1 
protein.  The HIF-1 mutant was transfected into HEK293 cells and the cells 
were exposed to hypoxia and reoxygenation.  The expression level of 
transfected mutant HIF-1 was higher compared to endogenous HIF-1 
expression in hypoxia (Figure 12).  If inhibition of mTORC1 is due to HIF-1, 
it would be expected that reactivation of mTORC1 is delayed upon 
reoxygenation.  However, overexpression of the stable HIF-1 mutant did not 






Figure 12. HIF-1α is not involved in mTORC1 regulation in hypoxia and 
reoxygenation.  A constitutively active mutant HIF-1α P402A/P564A (0.4 μg) 
was transfected into HEK293 cells for 3 days and placed in hypoxic condition 
for 4 hours at 1 % O2 followed by cell lysis at the indicated time points after 
reoxygenation.  
 
To further confirm this observation, I used the 786-O VHL null cells.  
These cells do not express HIF-1 and oxygen dependent regulation of HIF-
2 protein is prevented due to the absence of pVHL.  As shown in Figure 13, 
hypoxia still caused mTORC1 inhibition in the absence of a functional HIF 
pathway although to a slightly lesser extent compared to the VHL 
reconstituted cells.  Furthermore, knockdown of HIF-1α in HEK293 cells did 
not affect mTORC1 activity in hypoxia and upon reoxygenation compared to 
control siRNA (Figure 14A).  To rule out the involvement of the all the 3 HIF-
α isoforms, HIF-1β was silenced.  This prevents the formation of a functional 
dimeric HIF transcription factor.  HIF-1β knockdown did not prevent 
mTORC1 reactivation upon reoxygenation (Figure 14B).  Taken together, 






Figure 13. HIF-1α does not contribute to mTORC1 regulation in hypoxia and 
reoxygenation.  786-O cells with VHL null or reconstituted VHL-HA were 
grown to confluency and incubated in hypoxia (1 % O2) for 4 hours before cell 
lysis at the indicated time points upon reoxygenation.   
 
Figure 14. HIF-1α and HIF-1β are not involved in mTORC1 regulation in 
hypoxia and reoxygenation.  (A,B) HEK293 cells were transfected with 20 nM 
control, HIF-1α (A) or HIF-1β (B) siRNAs for 3 days and incubated in 
hypoxia for 4 hours at 1 % O2 followed by cell lysis at the indicated time 







3.2.4 The dynamic regulation of mTORC1 by hypoxia and reoxygenation 
is mediated via a post-translational mechanism   
 
So far, my results indicated that the dynamic regulation of mTORC1 
by cellular oxygen concentrations is independent of previously reported 
transcriptional mechanisms.  Furthermore, reactivation of mTORC1 upon 
reoxygenation is rapid.  These results suggest that mTORC1 regulation is 
independent of transcription.  To confirm this, the transcription and translation 
inhibitors actinomycin D and cycloheximide, respectively, were added to cells.  
Notably, the rapid mTORC1 reactivation was still observed in the presence of 
these inhibitors implying that regulation of mTORC1 is mediated via a 
posttranslational mechanism (Figure 15).   
 
Figure 15.  The dynamic regulation of mTORC1 in hypoxia and reoxygenation 
is mediated via a post-translational mechanism.  The transcription inhibitor 
actinomycin D (5 μg/ml) and translation inhibitor cycloheximide (40 μM) 
were added to HEK293 cells prior to incubation at 1 % O2 for 4 hours, 
followed by reoxygenation and cell lysis immediately (0 mins) as well as 5 







3.2.5 mTORC1 regulation in hypoxia and reoxygenation is independent of 
protein degradation 
 
 mTORC1 activity may be regulated by oxygen dependent changes in 
the stability of specific proteins (e.g. mTORC1 regulatory proteins). To 
determine if protein degradation is involved in the decrease in mTORC1 
activity in hypoxia as well as its reactivation upon reoxygenation, I used the 
proteasomal inhibitor MG-132 to block protein degradation.  If protein 
degradation is involved in oxygen dependent mTORC1 regulation, treatment 
with proteasome inhibitor would prevent inhibition of mTORC1 activity in 
hypoxia as well as its reactivation upon reoxygenation.  However, no change 
in mTORC1 activity was observed in cells treated with MG-132 compared to 
controls (Figure 16).  This indicates that mTORC1 activity is not regulated by 
changes in protein stability.  Similarly, when the Nedd8 E1 inhibitor 
MLN4924 which inhibits all cullin E3 ligases was used, no difference was 
observed in mTORC1 activity between MLN4924 treated and control cells 
(Figure 16).  This suggests that Cullin E3 ligases are not involved in mTORC1 
regulation in hypoxia and reoxygenation.  
Figure 16.  The dynamic regulation of mTORC1 in hypoxia and reoxygenation 
is independent of Cullin E3 ubiquitin ligases and protein degradation.  
MLN4924 (1 μM), an inhibitor of the Nedd8 activating enzyme (NAE) that 
blocks the activity of all Cullin E3 ligases, and proteasomal inhibitor MG-132 
(20 μM) were added to HEK293 cells prior to incubation at 1 % O2 for 4 hours, 





 In addition to proteasomal degradation, proteins are also degraded via 
the lysosomal pathway.  Hence, to test if lysosomal degradation plays a role in 
mTORC1 regulation in hypoxia and reoxygenation, lysosomal inhibitors 
ammonium chloride and Pepstatin A + E64 were used.  As shown in Figure 17, 
mTORC1 activity was inhibited in hypoxia and reactivated upon 
reoxygenation in the presence or absence of lysosomal inhibitors although 
treatment with ammonium chloride lead to a slight delay in mTORC1 
reactivation upon reoxygenation.  This indicates that mTORC1 activity is not 
regulated by lysosomal degradation pathway. 
 
Figure 17.  The dynamic regulation of mTORC1 in hypoxia and reoxygenation 
is independent of lysosomal degradation.  The lysosomal inhibitors 
ammonium chloride (20 mM) and pepstatin A (10 μM) plus E64 (25 μM) were 
added to HEK293 cells prior to incubation at 1 % O2 for 4 hours, followed by 
reoxygenation and cell lysis immediately (0 mins) as well as 5 and 15 min 









3.2.6 mTORC1 regulation in hypoxia and reoxygenation is independent of 
AMPK, mitochondrial ATP synthesis and reactive oxygen species (ROS) 
 
I next tested a number of potential post-translational mechanisms that 
may be involved in the regulation of mTORC1 by cellular oxygen 
concentrations.  AMPK is activated under conditions of energy stress such as 
during nutrient starvation or hypoxia whereby intracellular cellular ATP levels 
decline and AMP levels increase.  AMPK has been shown to inhibit mTORC1 
activity via phosphorylation of both TSC2 and the mTORC1 subunit Raptor 
(Liu et al., 2006; Gwinn et al., 2008).  To test for AMPK involvement in 
hypoxia and reoxygenation dependent mTORC1 regulation, I treated cells 
with compound C, an inhibitor of AMPK.  Compound C did not affect 
mTORC1 activity in hypoxia and reoxygenation (Figure 18).  Furthermore, 
treatment with an AMPK activator, AICAR, did not prevent mTORC1 
reactivation upon reoxygenation (Figure 18).   
Figure 18.  The dynamic regulation of mTORC1 in hypoxia and reoxygenation 
is independent of AMPK.  HEK293 cells were incubated for 4 hours at 1 % O2 
followed by reoxygenation and cell lysis at 0, 5 and 15 minutes.  Compound C, 
an inhibitor of AMPK (20 μM) and AICAR (0.5 mM) for AMPK activation 






I also mimicked the effect of hypoxia on cellular ATP concentrations 
by treating cells with various electron transport chain (ETC) inhibitors.  These 
inhibitors were used at concentrations that completely blocked oxidative 
phosphorylation.  Thus, the mitochondrial inhibitors would be expected to 
have a more pronounced effect on mTORC1 compared to hypoxia, which 
inhibits electron transport chain activity only partially.  However, the various 
mitochondrial inhibitors had a markedly weaker inhibitory effect on mTORC1 
activity compared to hypoxia (Figure 19).  As the ETC is reactivated upon 
reoxygenation, it is also possible that the reactivation of mTORC1 pathway is 
mediated by the increase in ATP levels upon reintroduction of oxygen.  Hence, 
the various mitochondrial inhibitors were added to inhibit ETC activation 
upon reoxygenation.  If mTORC1 activity is regulated by the ETC, mTORC1 
pathway would be completely inhibited upon reoxygenation in presence of the 
ETC inhibitors.  However, mTORC1 reactivation upon reoxygenation was 
observed in the presence of the various inhibitors, although at a slower rate 
(Figure 20).  Taken together, these results suggest that AMPK and 
mitochondrial ATP synthesis do not play a major role in mTORC1 regulation 
















Figure 19.  The dynamic regulation of mTORC1 in hypoxia and reoxygenation 
is independent of mitochondrial ATP synthesis.  HEK293 cells were treated 
with mitochondrial inhibitors FCCP (1 μM), myxothiazole (1 μM), oligomycin 
(10 μM) and antimycin A (1 μg/ml) under normoxic conditions or incubated in 







Figure 20. The dynamic regulation of mTORC1 upon reoxygenation is 
independent of mitochondrial ATP synthesis.  HEK293 cells were 
incubated for 4 hours at 1 % O2 followed by reoxygenation and cell lysis at 
0, 5 and 15 minutes.  Mitochondrial inhibitors FCCP (1 μM), myxothiazole 
(1 μM), oligomycin (10 μM) and antimycin A (1 μg/ml) were added prior 




To explain the rapid mTORC1 reactivation upon reoxygenation, I 
hypothesized that reactive oxygen species (ROS), a factor well known to be 
associated with reoxygenation, can induce mTORC1 activity.  ROS 
production during reoxygenation is largely a consequence of the highly 
reduced state of the ETC during hypoxia leading to a burst in ROS production 
upon reintroduction of oxygen.  However, my results show that the antioxidant 
N-acetylcysteine (NAC), the superoxide dismutase mimetic drug MnTBAP as 
well as the superoxide dismutase inhibitor Diethylditiolcarbamate (DCC) do 
not significantly affect mTORC1 reactivation upon reoxygenation (Figure 21).  
Furthermore, induction of cellular ROS by addition of 2-methoxyestradiol or 
glucose oxidase did not promote mTORC1 activity (Figure 21).  These results 
suggest that mTORC1 regulation during hypoxia and reoxygenation is 
















FIGURE 21.  The dynamic regulation of mTORC1 in hypoxia and 
reoxygenation is independent of reactive oxygen species (ROS).  HEK293 
cells were incubated for 4 hours at 1 % O2 followed by reoxygenation and cell 
lysis at 0, 5 and 15 minutes.  MnTBAP (50 μM), a superoxide dismutase (SOD) 
mimetic drug to decrease cellular superoxide production; SOD inhibitor 
Diethyldithiolcarbamate (DCC, 1 mM) to block H2O2 production; glucose 
oxidase (100 mU/ml) to generate H2O2, antioxidant N-acetylcysteine (NAC, 
10 mM) and 2ME2 (50 μM) to inhibit the ETC Complex I and SOD were 






Figure 22.  Summary of the functions of the different compounds used to study mTORC1 regulation in hypoxia and reoxygenation.  Antimycin A, 
myxothiazole, 2ME2 and oligomycin inhibits mitochondria electron transport chain.  MnTBAP decreases cellular superoxide production; SOD 
inhibitor Diethyldithiolcarbamate (DCC) blocks H2O2 production and glucose oxidase generates H2O2.  Compound C inhibits AMPK whereas 





3.2.7 mTORC1 activity in hypoxia and reoxygenation is sensitive to the 2-
oxoglutarate analog DMOG   
 
PHDs are dioxygenases that functions in an oxygen dependent manner.  
They are proposed to act as oxygen sensors as they require molecular oxygen 
for their function to post-translationally regulate the stability of HIF-1 
protein as well as a number of other more recently identified proteins 
including Activating Transcriptional Factor 4 (ATF4) (Koditz et al., 2007) 
myogenin (Fu et al., 2007), Pax2 (Yan et al., 2011) and -adrenergic Receptor 
(Xie et al., 2009).  Therefore, it is possible that PHDs also regulate mTORC1 
activity in hypoxia and reoxygenation.  To test the effect of PHDs in mTORC1 
regulation, I used the PHD inhibitors desferrioxamine (DFO), cobalt chloride 
(CoCl2) and dimethyloxalylglycine (DMOG) (Figure 11).  Treatment with the 
iron chelator DFO and with CoCl2 did not affect p70S6K phosphorylation 
even though they effectively inhibited PHD activity, as determined by the 
stabilization of HIF-1α (Figure 23A).  Longer incubation and higher 
concentrations of DFO were also without effect on mTORC1 activity (Figure 
23B).  However, DMOG, a 2-oxoglutarate (2OG) analog, completely blocked 










Figure 23.  mTORC1 activity in hypoxia and reoxygenation is independent of 
HIF-1α but sensitive to the 2-oxoglutarate analog dimethyloxalylglycine 
(DMOG).  (A) HEK293 cells were treated with HIF prolyl hydroxylase (PHD) 
inhibitors cobalt chloride (CoCl2, 200 μM), desferrioxamine (DFO, 200 μM) 
and the 2-oxoglutarate analog, dimethyloxalylglycine (DMOG, 2 mM) for 4 
hours under normoxic conditions.  (B) Two different concentrations of DFO 
(200 µM and 1 mM) were added to HEK293 alone or in combination with 
DMOG (2 mM) and incubated for either 4 hours or 12 hours in normoxia 
before cell lysis.   
 
Furthermore, the inhibitory effect of DMOG on mTORC1 was 
comparable to hypoxia (Figure 24).  Importantly, DMOG prevented 
reactivation of mTORC1 upon reoxygenation (Figure 24) but not CoCl2 or the 
HIF-1α inhibitor chetomin (Figure 25).  The inhibitory effect is also 
independent of protein degradation as treatment with proteasomal inhibitor 
MG-132 and the Nedd8 E1 inhibitor MLN4924 did not prevent mTORC1 
inhibition by DMOG (Figure 26).  Moreover, similar to oxygen regulation of 





be observed that mTORC1 activity is reactivated upon the removal of DMOG 
from cells (Figure 27). 
Figure 24.  mTORC1 activity in hypoxia and reoxygenation is independent of 
PHDs but sensitive to the 2-oxoglutarate analog dimethyloxalylglycine 
(DMOG).  DFO (200 µM) and DMOG (2 mM) were added to HEK293 cells 
prior to hypoxic incubation at 1 % O2 for 4 hours and cells were lysed at the 
indicated time points after reoxygenation.   
 
Figure 25.  mTORC1 activity in hypoxia and reoxygenation is independent of 
PHDs and HIF-1α.  Chetomin (50 nM) and CoCl2 (200 μM) were added to 
HEK293 cells prior to hypoxic incubation at 1 % O2 for 4 hours and cells were 












Figure 26. mTORC1 inhibition by DMOG is independent of Cullin E3 
ubiquitin ligases and protein degradation.  HEK293 cells were treated with 
DMOG (2 mM), the Nedd1 E1 inhibitor MLN4924 (1 μM) which inhibits all 
Cullin E3 ligases and the proteasome inhibitor MG-132 (20 μM) for 4 hours 
followed by cell lysis.  
 
Figure 27. DMOG washout reactivated mTORC1 activity.  HEK293 cells 
were treated with 2mM DMOG for 4 hours and removed by washing twice 
with 1X PBS followed by cell lysis at the indicated time points after washout.  
DMOG treated cells were lysed at 4 and 5 hours after DMOG treatment to 







To characterize how DMOG regulates mTORC1 activity, I looked at 
different proteins in the mTORC1 pathway to better understand the 
mechanism of action of DMOG on mTORC1 regulation.  It can be observed 
that DMOG reduced mTOR phosphorylation at both serine 2448 and 2481 
residues (Figure 28A).  This indicates that the effect of DMOG is at the level 
of mTOR or upstream of mTOR.  No change was observed in the expression 
levels of GL, Raptor (unique to mTOR complex1) as well as Rictor (specific 
to mTOR complex 2) (Figures 28A and B).  This shows that these proteins are 
not targets of DMOG.  
 
Figure 28.  DMOG treatment decreased mTOR phosphorylation.  (A) 
HEK293 cells were treated with 2 mM DMOG for 4 hours followed by cell 
lysis.  (B) Components of mTOR complex 1 and 2. 
 
However, a slight mobility shift of Rictor was observed with treatment 
of DMOG (Figure 28).  Therefore, it is possible that DMOG also regulates 
mTORC2.  If DMOG regulates both mTORC1 and mTORC2 pathways, it is 





activator of the mTORC1 pathway located upstream of TSC1/2 that is 
phosphorylated at threonine 308 and serine 473 when it is active (Figure 1).  It 
is a downstream target of mTORC2 that is phosphorylated at serine 473 when 
mTORC2 is active.  It is plausible that if DMOG inhibits mTORC2, Akt 
phosphorylation and activation would in turn be reduced and this would lead 
to the inhibition of mTORC1.  Hence, I looked at the effect of DMOG 
treatment on Akt phosphorylation.  As shown in Figure 29, DMOG treatment 
led to a slight reduction of Akt phosphorylation at S473.  However, no change 
was observed at Akt T308 phosphorylation site (Figure 29).  This result 
indicates that the effect of DMOG on mTORC1 is independent of mTORC2 
and Akt.   
 
 
Figure 29. Regulation of 
mTORC1 activity is 
independent of Akt.  
HEK293 cells were 
treated with 2mM 
DMOG or incubated at 
1 % O2 for 4 hours 
followed by cell lysis at 




So far, my results showed that the effect of DMOG on mTORC1 
inhibition is downstream of Akt and upstream of or at the level mTOR.  Hence, 
I tested if the effect of DMOG is upstream of mTOR using a constitutively 
active Rheb mutant.  Mutation of residue serine 16 on Rheb to histidine (S16H) 
results in a mutant Rheb that exhibits gain-of-function properties (Yan et al., 





phosphorylation (Figure 30).  However, Rheb S16H overexpression did not 
prevent mTORC1 inhibition upon treatment of DMOG (Figure 30).  This 
indicates that the effect of DMOG may be at the level of Rheb or downstream 
of Rheb.  
 
Figure 30.  mTORC1 regulation 
by DMOG is not at the level of 
Rheb. HEK293 cells were 
transfected with 0.4 g FLAG-
Rheb S16H pcDNA3 for 3 days 
and treated with DMOG for 4 




However, it has been reported that the constitutively active Q64L Rheb 
mutant is sensitive to TSC2 overexpression (Li, Inoki and Guan, 2004).  
Although this was not shown for the S16H mutant I used, I also tested if TSC2 
is involved in mTORC1 regulation.  It has previously been shown that AMPK 
regulates mTORC1 pathway by phosphorylating TSC2 and enhancing its 
inhibitory activity (Inoki, Zhu and Guan, 2003).  Therefore, I looked at the 
involvement of TSC1/2 in mTORC1 regulation by DMOG and also in hypoxia 




 MEFs were treated with DMOG to 
determine if the absence of TSC2 affects the effect of DMOG on mTORC1 
activity.  As expected, in TSC2
+/+
 cells, DMOG inhibited mTORC1 activity as 
shown by the reduced p70S6K phosphorylation (Figures 31A and B).  
However, interestingly, treatment of DMOG did not affect mTORC1 activity 
in TSC2
-/-
 cells (Figures 31A and B).  This suggests that DMOG regulation of 






TSC2 forms a functional complex with TSC1 and the interaction 
between TSC1 and TSC2 is required to prevent TSC2 ubiquitination 
(Benvenuto et al., 2000).  Hence, to test if DMOG affects the formation of 
TSC1/2 complex, I performed immunoprecipitation to pull down TSC2-FLAG 
in the presence or absence of DMOG.  As shown in Figure 32, treatment of 
DMOG did not affect TSC1 binding to TSC2.  This indicates that the effect of 


















Figure 31.  The effect of DMOG on 
mTORC1 activity may be regulated 





 cells were treated with 
2 mM DMOG for 4 hours followed 
by cell lysis. The amount of cell 
lysates loaded in (B) was adjusted 
to show equal phosphorylation 











Figure 32.  The effect of 
DMOG on mTORC1 
inhibition is independent of 
TSC1/2 complex formation.  
HEK293 cells were 
transfected with 1.5 g 
FLAG-TSC2 pcDNA3 in 60 
mm tissue culture plates for 3 
days followed by cell lysis 
and immunoprecipitation with 
FLAG antibody as described 











Next, I tested if regulation of mTORC1 activity by hypoxia and 
reoxygenation is also mediated by TSC2.  Surprisingly, unlike DMOG, the 
effect of hypoxia on mTORC1 activity in TSC2
+/+
 MEFs is weak (Figures 33 
and 34) although mTORC1 is reactivated upon reoxygenation (Figure 34).  
These results suggest that the effect of DMOG and hypoxia on mTORC1 























Figure 33.  Hypoxia and DMOG may work via different mechanisms to 




 cells were treated with 
2 mM DMOG or incubated at 1 % O2 for 4 hours followed by cell lysis.  
 
 
Figure 34.  Hypoxia and reoxygenation had a weak effect on mTORC1 
activity in MEF TSC2
+/+




 cells were treated 
with 2 mM DMOG or incubated at 1 % O2 for 4 hours followed by cell lysis at 










It is interesting that even though hypoxia did not have a marked effect 
on mTORC1 activity in TSC2
+/+
 cells, changes in oxygen levels had no effect 
on mTORC1 activity in TSC2
-/-
 cells (Figures 33 and 34).  Hence, to 
determine if TSC2 plays a role in mTORC1 regulation in response to hypoxia 
and reoxygenation, I overexpressed TSC2 in the TSC2
-/-
 cells.  If TSC2 plays 
a role in the regulation of mTORC1 activity, reintroduction of TSC2 would 
enable the TSC2
-/-
 cells to sense changes in oxygen levels.  Overexpression of 
TSC2 to the TSC2
-/-
 MEFs resulted increased sensitivity to DMOG but not 
hypoxia (Figure 35).  This suggests that it is unlikely that the effect of hypoxia 









Figure 35.  Overexpression of TSC2 in TSC2
-/-
 cells did not lead to hypoxia 
induced mTORC1 inhibition.  MEF TSC2
-/-
 cells were transfected with 1 g 
FLAG-TSC2 pcDNA3 for 3 days.  All cells were treated with 2 mM DMOG 









As the mTORC1 pathway in TSC2
+/+
 MEF cells was not inhibited in 





 MEF cells to determine if mTORC1 regulation in hypoxia is regulated 
by TSC2.  Hence, I used HEK293 cells to perform overexpression and 
knockdown studies.  Overexpression of TSC2 did not affect mTORC1 activity 
in hypoxia and reoxygenation compared to controls (Figure 36).  Knockdown 
of TSC2 in HEK293 cells partially blocked the inhibitory effect of DMOG on 
mTORC1 (Figure 37) but did not affect the regulation of mTORC1 by hypoxia 
and reoxygenation (Figure 38).  Taken together, these results indicate that the 





Figure 36.  TSC2 is not involved in mTORC1 regulation in hypoxia and 
reoxygenation.  HEK293 cells were transfected with 0.4 g FLAG-TSC2 
pcDNA3 and incubated at 1 % O2 for 4 hours followed by cell lysis at the 









Figure 37.  TSC2 knockdown 
partially reverses the effect of 
DMOG on mTORC1.  HEK293 
cells were transfected with 20 
nM control or TSC2 siRNA for 
3 days followed by treatment 
with 2mM DMOG and cell 






Figure 38.  Regulation of mTORC1 activity in hypoxia and reoxygenation is 
independent of TSC2.  HEK293 cells were transfected with 20 nM control or 
TSC2 siRNA for 3 days and incubated at 1 % O2 for 4 hours followed by cell 











The lack of effect of the known PHD inhibitors, DFO and CoCl2, 
suggests that the DMOG dependent mTORC1 regulation is independent of 
PHD enzymes.  Alternatively, it is also possible that DFO and CoCl2 mediated 
mTORC1 inhibition is masked by a simultaneous, PHD independent activation 
of mTORC1 by these inhibitors.  To test this possibility, I treated HEK293 
cells with DMOG in the presence of either DFO or CoCl2.  If DFO and CoCl2 
activate mTORC1 in a PHD independent manner, it would be expected that 
the two inhibitors reverse the effect of DMOG.  However, DMOG mediated 
inhibition of mTORC1 was reversed by DFO to a small degree but not 
affected by CoCl2 (Figure 39) suggesting that these iron chelators do not 
activate mTORC1 via a PHD independent pathway.  Therefore, I conclude 
that PHD enzymes are unlikely to be involved in the oxygen dependent 















Figure 39.  mTORC1 activity in hypoxia and reoxygenation is independent of 
HIF-1α but sensitive to the 2-oxoglutarate analog dimethyloxalylglycine 
(DMOG).  HEK293 cells were treated with PHD inhbitors DFO (200 µM), 
CoCl2 (200 µM) and DMOG (2 mM) alone or in the indicated combinations 







In support of these results, knockdown of the three HIF PHDs (PHD1-
3) and the 2OG dependent Factor Inhibiting HIF (FIH) in HEK293 cells did 
not reveal differences in p70S6K phosphorylation levels compared to control 
(Figure 40).  Furthermore, I also confirmed that the effect of DMOG is HIF 
independent by treating 786-O VHL null cells with DMOG.  As shown in 
Figure 41, DMOG inhibited mTORC1 activity in VHL null cells indicating 
that the inhibitory effect of DMOG on mTORC1 is independent of HIF.  
Collectively, these data suggest that a DMOG sensitive 2-OG dependent 
dioxygenase enzyme might be responsible for the regulation of mTORC1 
activity. 
Figure 40.  mTORC1 activity is independent of the three HIF PHDs (PHD1-3) 
and the 2OG dependent Factor Inhibiting HIF (FIH).  HEK293 cells were 
transfected with 20 nM control, HIF PHDs (PHD1-3) and FIH siRNAs for 3 






Figure 41.  mTORC1 activity is independent of HIF-1α but sensitive to the 2-
oxoglutarate analog dimethyloxalylglycine (DMOG).  786-O VHL null and 







To determine the dioxygenase that regulates mTORC1 activity, 11 
possible candidate dioxygenases were selected for siRNA screening using two 
different siRNAs each.  These candidates included dioxygenases with known 
cytoplasmic subcellular localization, enzymes with known metabolic function 
as well as family members that are not well characterized functionally.  I 
identified phosphatidylserine receptor (PTDSR) and heat shock 27kDa 
associated protein 1 (HSPBAP1) as possible candidates from the screening 
(Figure 42).   
Figure 42.  mTORC1 activity is not regulated by oxygen and 2-oxoglutarate 
dependent dioxygenases.  HEK293 cells were transfected with 20 nM control 
siRNAs or two different siRNAs for each of the candidate dioxygenase for 3 









However, hypoxia and reoxygenation experiments upon siRNA 
mediated silencing of the enzymes showed that only HSPBAP1 knockdown 
delayed mTORC1 reactivation upon reoxygenation (Figure 43B) whereas 
PTDSR knockdown did not have any effect on mTORC1 activity (Figure 
43A).  I therefore hypothesized that inhibition of mTORC1 upon hypoxia or 
DMOG treatment is due to HSPBAP1 inhibition.  Hence, it can be predicted 
that overexpression of HSPBAP1 would reverse the effect of hypoxia and 
DMOG.   
Figure 43.  mTORC1 activity is not regulated by the oxygen and 2-
oxoglutarate dependent dioxygenases, PTDSR and HSPBAP1.  (A, B) The 
siRNA for the two candidate dioxygenases, PTDSR  (A) and HSPBAP1 (B) 
with positive mTORC1 inhibition were transfected (20 nM) to HEK293 cells 
for 3 days and incubated in hypoxia for 4 hours at 1 % O2 followed by cell 








However, contrary to my hypothesis, it was observed that HSPBAP1 
overexpression was without effect on hypoxia and DMOG mediated mTORC1 
inhibition (Figure 44).  This suggests that HSPBAP1 does not regulate 
mTORC1 activity.  To rule out the possibility that the DMOG and oxygen 
concentrations used inhibited HSPBAP1 completely, even when 
overexpressed, I used lower concentrations of DMOG (Figure 45) or a less 
severe hypoxia treatment (Figure 46).  However, HSPBAP1 overexpression 
did not have an effect on mTORC1 activity compared to vector control under 
these conditions indicating that HSPBAP1 is not a regulator of mTORC1. 
Figure 44.  mTORC1 activity is not regulated by the oxygen and 2-
oxoglutarate dependent dioxygenase, HSPBAP1 in hypoxia and with DMOG 
treatment.  HSPBAP1-FLAG or empty pcDNA3 vectors (0.4 g) were 
transfected into HEK293 cells for 3 days before DMOG treatment (2 mM) or 














Figure 45.  mTORC1 activity is not regulated by the oxygen and 2-
oxoglutarate dependent dioxygenase, HSPBAP1 with different concentrations 
of DMOG.  HEK293 cells were transfected with empty pcDNA3 or 
HSPBAP1-FLAG (0.4 g) for 3 days followed by treatment with the indicated 
concentration of DMOG for 4 hours.  
 
Figure 46.  mTORC1 activity is not regulated by the oxygen and 2-
oxoglutarate dependent dioxygenase, HSPBAP1 under different hypoxic 
conditions.  HEK293 cells were transfected with empty pcDNA3 or 
HSPBAP1-FLAG (0.4 g) for 3 days followed by incubation in hypoxic 
condition with 1 % or 5 % O2 for 4 hours.  
 
 















 My results indicated that 2-oxoglutarate dioxygenases are not involved 
in mTORC1 regulation although DMOG completely inhibited mTORC1 
activity in hypoxia and reoxygenation.  Therefore, to further verify the 
inhibition of mTORC1 activity by DMOG, I tested if other inhibitors of 2-
oxoglutarate dioxygenases affect mTORC1 activity.  N-(2-Mercaptopropionyl) 
glycine (NMPG) is a 2-oxoglutarate analog which functions similarly as 
DMOG to act as a competitive inhibitor to 2-oxoglurate dependent 
dioxygenases (Wang et al., 2002) (Figure 47).  NMPG inhibits the function of 
PHDs, hence, as expected, HIF-1α protein is not degraded when oxygen is 
reintroduced in the presence of NMPG (Figure 48).  The effect of NMPG on 
HIF-1α stability upon reoxygenation is markedly stronger than DMOG 
indicating that NMPG may be a stronger inhibitor.  However, treatment of 
NMPG did not affect mTORC1 activity in hypoxia and reoxygenation when 
compared to controls.  In contrast to DMOG treatment, NMPG did not inhibit 
mTORC1 reactivation when oxygen is reintroduced (Figure 48). 
 
Figure 47.  2-oxoglutarate and its analogs dimethyloxalylglycine (DMOG), N-






Figure 48.  mTORC1 activity in hypoxia and reoxygenation is sensitive to 
DMOG but not N-(2-Mercaptopropionyl) glycine (NMPG).  NMPG (5 mM) 
and DMOG (2 mM) were added to HEK293 cells prior to hypoxic incubation 
at 1 % O2 for 4 hours and cells were lysed at the indicated time points after 
reoxygenation.   
 
 Ethyl 3,4-dihydroxybenzoate (EDHB) is also a 2-oxoglutarate analog 
that has been shown to inhibit 2-oxoglutarate dependent dioxygenases 
including PHDs (Warnecke et al., 2003) and collagen prolyl 4-hydroxylases 
(Majamaa, Sasaki and Uitto, 1987; Sasaki, Majamaa and Uitto, 1987) (Figure 
47).  It would be expected that EDHB treatment would prevent mTORC1 
reactivation upon reoxygenation if it functions similarly as DMOG.  However, 
mTORC1 activity was not inhibited in the presence of EDHB when oxygen 
was reintroduced (Figure 49).  Taken together, these results indicate that 2-
oxoglutarate dependent dioxygenases are not regulators of mTORC1 activity 
in hypoxia and reoxygenation.  The inhibition of mTORC1 by DMOG may be 









Figure 49.  mTORC1 activity in hypoxia and reoxygenation is sensitive to 
DMOG but not Ethyl 3,4-dihydroxybenzoate (EDHB).  EDHB (400 µM) and 
DMOG (2 mM) were added to HEK293 cells prior to hypoxic incubation at 
1 % O2 for 4 hours and cells were lysed at the indicated time points after 
reoxygenation.   
 
As a further confirmation of the 2-oxoglutarate analogs results to show 
that mTORC1 regulation is independent of 2-oxoglutarate dependent 
dioxygenases, I performed overexpression of Isocitrate dehydrogenase 1 
(IDH1).  IDH1 are enzymes that catalyze the conversion of isocitrate to 2-
oxoglutarate in the Krebs Cycle (Figure 50).  It has been reported that a 
mutation at arginine 132 of IDH1 to histidine (R132H) found in gliolastomas 
resulted in the conversion of 2-oxoglutarate to 2-hydroxyglutarate (2HG) 
(Dang et al., 2009).  Consequently, this IDH1 R132H mutation leads to the 
reduction of 2-oxoglutarate and accumulation the dioxygenase competitive 
inhibitor 2HG.  Therefore, if mTORC1 is regulated by 2-oxoglutarate 
dependent dioxygenases, I would expect mTORC1 activity to be inhibited 
when IDH1 R132H mutant is overexpressed in cells due to the increased 
levels of 2HG.  However, no change was observed in mTORC1 activity with 
the overexpression of wild type as well as R132H mutant IDH1 (Figure 51).  

















Figure 51.  Regulation of mTORC1 
activity is independent of 2-
oxoglutarate.  (A) HEK293 cells 
were transfected with 0.4 μg 
pcDNA3 vector control, IDH1 
R132H mutant or IDH1 wt pcDNA3 










3.2.8 mTORC1 activity is not regulated by DEPTOR, PRMT1, Siah2 and 
SV40 T Antigen   
 
 To identify proteins that regulate mTORC1 activity in hypoxia, I tested 
several candidate proteins to determine if they affect mTORC1 activity.  These 
proteins were selected based on several different criteria, including their 
function as inhibitors of the mTORC1 pathway or their upregulation in 




DEPTOR is an inhibitor of mTORC1 and mTORC2. The DEPTOR 
protein interacts via its PDZ domain with the FAT domain of mTOR (Peterson 
et al., 2009).  DEPTOR (also known as DEPDC6) is named in reference to its 
DEP (Dishevelled, Egl-10, Pleckstrin) domains and its specific interaction 
with mTOR.  The expression level of DEPTOR is low in most cancers, 
consistent with the fact that many human cancers have activated mTORC1 and 
mTORC2 pathways (Peterson et al., 2009).  However, no studies have looked 
at the activity and expression of DEPTOR in hypoxia.  Hence, to test if 
DEPTOR might regulate mTORC1 activity in hypoxia, I performed 
overexpression of DEPTOR.  No changes in mTORC1 activity were observed 
with the overexpression of DEPTOR compared to controls in both normoxia 
and hypoxia (Figure 52A).  This indicates that regulation of mTORC1 activity 




DEPTOR overexpression is not sufficient to inhibit mTORC1 activity as no 
decrease in p70S6K phosphorylation was observed (Figure 52A).  
 
Interestingly, a mobility shift was observed in hypoxia when lower 
amount of DEPTOR was overexpressed, suggested a change in DEPTOR 
posttranslational modification (Figure 52B).  The significance of this finding 
is currently not clear.  Of note, it has been reported that the phosphorylation of 
DEPTOR facilitates binding and ubiquitylation by the F box protein TrCP 
thereby leading to its proteasomal degradation (Dang et al., 2009; Gao et al., 
2011; Zhao, Xiong and Sun, 2011).  It is therefore possible that oxygen 
concentrations affect the stability of endogenous DEPTOR protein. 
 
 
Figure 52.  mTORC1 activity is not regulated by DEPTOR.  (A) HEK293 
cells were transfected with 0.4 μg pcDNA3 vector control or DEPTOR-FLAG 
pcDNA3 for 3 days followed by hypoxia incubation for 4 hours at 1 % O2 
before lysis.  (B) HEK293 cells were transfected with 0.15 μg DEPTOR-
FLAG pcDNA3 for 3 days followed by hypoxia incubation for 4 hours at 1 % 









 Protein arginine methyl-transfecrases (PRMTs) are a family of 
enzymes that catalyze protein arginine methylation.  PRMTs methylate 
arginine residues within an Akt consensus phosphorylation motif (RxRxxS/T) 
in their target proteins.  This methylation blocks the phosphorylation of Akt on 
these substrates (Sakamaki et al., 2011; Yamagata et al., 2008).  As Akt is an 
important upstream activator of the mTORC1 pathway (Figure 1), it is 
possible that PRMTs regulate the mTORC1 pathway by inhibiting the 
phosphorylation of Akt target proteins.  Therefore, to test this, I overexpressed 
PRMT1 in cells.  No difference was observed in cells with PRMT1 
overexpression compared to controls (Figure 53).  Similarly, mTORC1 
activity was not affected by PRMT1 in hypoxia or with DMOG treatment 
(Figure 53).  This result indicates that PRMT1 is unlikey to be involved in 








Figure 53.  PRMT1 is not involved in mTORC1 regulation.  HEK293 cells 
were transfected with 0.4 μg pcDNA3 vector control or PRMT1-V5 pcDNA3 
for 3 days followed by hypoxia incubation at 1 % O2 or DMOG (2mM) 





3.2.8.3 Siah2  
  
The ubiquitin ligase Siah 2 is upregulated in hypoxia and functions to 
degrade PHD1 and 3 (Nakayama et al., 2004; Nakayama, Qi and Ronai, 2009).  
Although PHD2 is reported to be the most important PHD under normoxia 
(Berra et al., 2003), PHD3 appears to retain its activity in mediating HIF-1 
hydroxylation in hypoxia (Nakayama et al, 2004).  Hence, degradation of 
PHD3 facilitates HIF-1 stabilization in hypoxia, leading to the transcription 
of its downstream targets.   
 
Recently, it has been discovered that Siah2 protein is itself regulated 
and stabilized by a member of the tumor necrosis factor receptor superfamily, 
p75
NTR
.  In hypoxia, Siah2 is bound to the soluble domain of the adaptor 
protein p75
NTR
, which functions to stabilize Siah2 and prevent its 
autoubiquitination (Le Moan et al., 2011).  Therefore, as Siah2 is upregulated 
in hypoxia, it is possible that Siah2 regulates the mTORC1 pathway in 
hypoxia.  However, I found that overexpression of Siah2 in normoxia to 
mimic the increased Siah2 levels in hypoxia did not affect mTORC1 activity 
(Figure 54).  This result suggests that mTORC1 regulation in hypoxia is 
independent of Siah2.  
 
Figure 54. Siah 2 is not involved in 
mTORC1 regulation.  HEK293 cells 
were transfected with 0.4 μg pcDNA3 
vector control or Siah2-FLAG 
pcDNA3 for 3 days followed by 
hypoxia incubation for 4 hours at 1 % 







3.2.8.4 SV40 T Antigen 
 
In addition to the cell lines used in Figure 4, I also used HEK293T 
cells to study mTORC1 activity in hypoxia and reoxygenation.  As expected, 
mTORC1 activity is inhibited in hypoxia, as shown by the decrease in p70S6K 
phosphorylation (Figure 55).  However, interestingly, mTORC1 activity 
remained inhibited upon reoxygenation and a delay in mTORC1 reactivation 
was observed (Figure 55).  This is surprising as the HEK293T cells are a 
variant of the original HEK293 cells with an addition of the SV40 Large T 
antigen.  Hence, it is possible that the presence of the SV40 Large T antigen in 
HEK293 cells affects mTORC1 reactivation upon reoxygenation. 
Figure 55.  mTORC1 reactivation upon reoxygenation is delayed in HEK293T 
cells.  HEK293T cells were incubated at 21 % or 1 % O2 for 4 hours, followed 
by reoxygenation in normoxia and cell lysis at the indicated time points. 
 
 To test this, knockdown of SV40 Large T antigen was carried out in 
HEK293T cells.  If the SV40 Large T antigen were involved in mTORC1 
inhibition upon reoxygenation, knockdown of SV40 Large T-antigen would 
result in a rapid reactivation of mTORC1 activity similar to the rate observed 





control and SV40 Large T antigen knockdown cells (Figure 56).  This 
indicates that SV40 Large T antigen is not involved in mTORC1 regulation. 
Figure 56.  mTORC1 activity in hypoxia and reoxygenation is not regulated 
by SV40 large T Antigen.  HEK293T cells were transfected with 20 nM 
control or SV40 Large T antigen siRNA for 3 days and incubated in hypoxia 
for 4 hours at 1 % O2 followed by cell lysis at the indicated time points after 
reoxygenation. 
 
 To confirm the result, I overexpressed SV40 Large T antigen in 
HEK293 cells to mimic the presence of SV40 Large T antigen in HEK293T 
cells.  Overexpression of SV40 Large T antigen did not affect mTORC1 
reactivation upon reoxygenation (Figures 57A and B).  Taken together, these 
results show that SV40 Large T antigen is not involved in the regulation of 












 Figure 57.  SV40 Large T Antigen is not involved in mTORC1 regulation in 
hypoxia and reoxygenation.  (A and B) HEK293 cells were transfected with 
0.4 μg pcDNA3 vector control, SV40 Large T Antigen pcDNA3 (A) or SV40 
Large T Antigen pcDNA4/TO (B) for 3 days with 1 μg/ml tetracycline 
induction for (B) at the last 24 hours prior to cell lysis. Cells were incubated 
for 4 hours at 1 % O2 followed by cell lysis at the indicated time points after 
reoxygenation. 
 
In addition to the Large T antigen, the SV40 vector also encodes an 
alternatively spliced gene known as the Small T antigen.  Hence, to test if the 
SV40 Small T antigen is involved in mTORC1 regulation, overexpression of 
the SV40 Small T antigen alone or in combination with the SV40 Large T 
antigen was carried out.  No difference in mTORC1 reactivation was observed 
upon reoxygenation in the presence of the SV40 Small T antigen (Figure 58) 
or both SV40 Large and Small T antigens (Figure 59).  Taken together, these 
results showed that SV40 Large and Small T antigens are not involved in 






HEK293T cells upon reoxygenation may be due to other secondary changes in 
these cells independent of the SV40 T antigens.  
 
Figure 58.  mTORC1 activity is not regulated by Small T antigen.  HEK293 
cells were transfected with 0.4 μg pcDNA3 vector control or SV40 Small T 
Antigen pcDNA3 for 3 days and incubated for 4 hours at 1 % O2 followed by 
cell lysis at the indicated time points after reoxygenation. 
 
 
Figure 59.  mTORC1 activity is not regulated by SV40 Large and Small T 
antigen.  HEK293 cells were transfected with 0.4 μg pcDNA3 vector control, 
SV40 Large T Antigen pcDNA3 or SV40 Small T Antigen pcDNA3 for 3 
days and incubated for 4 hours at 1 % O2 followed by cell lysis at the indicated 









3.2.9 mTORC1 activity in hypoxia and reoxygenation is regulated at the 
level of the mTORC1 complex directly   
 
mTORC1 is activated by two independent signaling pathways in 
response to different upstream signals.  Growth factors activate mTORC1 
through the inactivation of the TSC1/2 complex whereas amino acids 
availability activates mTORC1 via the Ragulator-Rag GTPase complex 
resulting in its translocation to the lysosomes.  To determine if hypoxia exerts 
its inhibitory effect via the TSC1/2 pathway, I deprived cells of amino acids.  
Under these conditions, only the serum dependent TSC1/2 pathway will be 
active.  In the absence of amino acids, mTORC1 activity in normoxia was low 
but detectable (Lane 1 in Figure 60).  In the absence of amino acids, hypoxia 
completely inhibited mTORC1 activity and the effect was rapidly reversed 
upon reoxygenation (Figure 60).  This suggests that hypoxia can inhibit 
mTORC1 activity via the serum dependent TSC1/2 pathway.    On the other 
hand, to test if hypoxia also acts on the amino acids dependent Ragulator-Rag 
GTPase pathway, serum deprivation was carried out to inhibit mTORC1 
activation via the TSC1/2 pathway.  Thus only the Ragulator-Rag GTPase 
would be responsible for mTORC1 activity (Figure 60).  mTORC1 was 
completely inhibited in hypoxia and this inhibition was rapidly reversed upon 
reintroduction of oxygen.  This suggests that hypoxia could also work via the 
Ragulator-GTPase pathway to regulate mTORC1 activity.  One potential 
interpretation of my results is that hypoxia exerts its effect on two independent 
pathways to affect mTORC1 activity.  However, it is highly unlikely that 




signaling pathways.  It is therefore much more probable that hypoxia inhibits 
at a common downstream target of both pathways.  Because hypoxia inhibits 
the phosphorylation of all known mTORC1 targets, the target of oxygen 
dependent regulation of the mTORC1 pathway is likely the mTORC1 complex 
itself.   
Figure 60.  mTORC1 activity in hypoxia and reoxygenation is regulated at the 
level of mTORC1.  HEK293 cells were pre-treated with serum and amino acids 
free Krebs buffer with 25 mM glucose for 1 hour, followed by addition of 
10% serum or amino acids to the Krebs buffer.  Cells were then incubated for 
4 hours at 1 % O2 followed by reoxygenation and cell lysis at the indicated 






3.2.10 mTORC1 may be regulated by heme binding proteins in hypoxia 
and reoxygenation   
 
My experiments suggest that hypoxia inhibits mTORC1 via a post-
translational mechanism by directly regulating the mTORC1 complex.  As I 
have ruled out the involvement of the 2-oxoglutarate and oxygen dependent 
dioxygenases in mTORC1 regulation, I hypothesized that oxygen dependent 
heme containing proteins mediate mTORC1 regulation.  To test the hypothesis, 
I used a number of general inhibitors of heme containing proteins.  
Interestingly, under basal conditions, inhibition of heme binding proteins with 
treatment of sodium azide and the NO donor, GSNO, both mimicked the effect 
of hypoxia by inhibiting mTORC1 activity (Figure 61).  Furthermore, upon 
reoxygenation, sodium azide treatment prevented mTORC1 reactivation 
(Figure 62).  These results suggest that heme binding proteins may be 
involved in mTORC1 regulation in hypoxia and reoxygenation.  As some of 
the mitochondria ETC proteins including cytochrome c oxidase also belong to 
the heme binding protein family, it is possible that the inhibitors of heme 
binding proteins regulate mTORC1 activity via inhibition of mitochondrial 
ETC proteins.  However, the cytochrome c oxidase inhibitor potassium 
cyanide (KCN) did not have any effect on mTORC1 activity (Figure 61).  
Furthermore, treatment with other mitochondrial inhibitors did not result in 
marked inhibition of mTORC1 activity (Figure 19).  This shows that the 
inhibitory effect of the heme binding protein inhibitors is not mediated 




mTORC1 in hypoxia is mediated via an oxygen dependent, heme containing 
protein that is not part of the mitochondrial ETC. 
 
Figure 61.  Regulation of mTORC1 
activity in hypoxia and 
reoxygenation may involve heme 
binding proteins.  HEK293 cells 
were treated with inhibitors of 
heme binding proteins: sodium 
azide (1 mM), potassium cyanide 
(KCN, 1 mM) and S-
Nitrosoglutathione (GSNO, 1 mM) 


















Figure 62.  Regulation of mTORC1 activity in hypoxia and reoxygenation may 
involve heme binding proteins.  HEK293 cells were pre-incubated at 1 % O2 in 
the hypoxia workstation for 4 hours and sodium azide (1 mM) was added to 










3.3 Discussion  
 
Hypoxia is one of the major signals that regulate mTORC1 activity.  
However, the involved mechanisms are currently not well understood.  In this 
study, I show that hypoxia dependent inhibition of mTORC1 is highly 
dynamic and rapidly reversed (within 15 minutes) upon reintroduction of 
oxygen.  This suggests that regulation of mTORC1 by changes in oxygen 
concentrations is primarily mediated via post-translational mechanisms.  
Indeed, my results indicate that oxygen dependent mTORC1 regulation is 
intact in the absence of ongoing transcription and translation.  Furthermore, 
consistent with previous reports (Arsham, Howell and Simon, 2003; Liu et al., 
2006), my results show that HIF, the major transcription factor induced under 
hypoxia, is not involved in mTORC1 regulation.   
 
In further experiments, I tested a number of potential mediators that 
may play a role in the regulation of mTORC1 signaling in hypoxia and 
reoxygenation.  REDD1, a known transcriptional target of HIF, has been 
reported to inhibit mTORC1 in a TSC1/2 dependent manner although the 
exact mechanism is currently unknown.  My results showed that REDD1 is 
not involved in the rapid regulation of mTORC1.  This is based on a number 
of findings, including the lack of significant effect of REDD1 overexpression 
as well as silencing of both REDD1 and 2 paralogs on mTORC1 activity in 
normoxia and hypoxia.  Furthermore, the rapid reactivation of mTORC1 
during reoxygenation was not accompanied by a concomitant downregulation 




mTORC1 was strongly inhibited in the tested cell lines.  However, REDD1 
induction by hypoxia was cell line dependent.  The observed difference in 
REDD1 expression levels under hypoxia in the different cell lines tested is in 
line with the findings of another study which showed that REDD1 regulation 
of mTORC1 in hypoxia is cell type specific (Wolff et al., 2011).  It should also 
be noted that REDD1 has been reported to mediate mTORC1 inhibition under 
hypoxia as a result of its HIF dependent transcriptional upregulation 
(Brugarolas et al., 2004).  However, given that HIF was not required for the 
dynamic oxygen dependent regulation of mTORC1 in my experiments, 
REDD1 is likely not a major mediator of oxygen dependent regulation of 
mTORC1 under these conditions. 
 
Another important upstream regulator that may mediate the dynamic 
regulation of mTORC1 in hypoxia is AMPK.  Low oxygen concentrations 
inhibit mitochondrial oxidative phosphorylation, thereby leading to reduced 
ATP production and subsequently, activation of AMPK.  AMPK is known to 
phosphorylate TSC2 directly to regulate mTORC1 activity in hypoxia (Liu et 
al., 2006).  In addition, AMPK has been shown recently to regulate mTORC1 
independent of TSC1/2 by phosphorylating the mTORC1 subunit Raptor 
directly to induce 14-3-3 binding (Gwinn et al., 2008).  Although these reports 
showed that AMPK plays an important role in mTORC1 regulation, other 
studies concluded that AMPK is not involved in mTORC1 regulation in 
hypoxia (Arsham, Howell and Simon, 2003; Brugarolas et al., 2004).  The 
results of my study suggest that AMPK is not a major regulator of mTORC1 




experiments using small molecule inhibitor and activator of AMPK.  
Furthermore, complete blocking of mitochondrial ATP production using 
various inhibitors exerted smaller inhibitory effects on mTORC1 compared to 
incubation of cells at 1 % oxygen where oxidative phosphorylation is still 
partially functional (Chua et al., 2010).  This indicates that hypoxia functions 
at least partially via oxidative phosphorylation and AMPK independent 
mechanisms.   
 
mTORC1 is activated via two different pathways, the growth factor 
dependent TSC1/2 pathway or the amino acids dependent Ragulator-Rag 
complex pathway.  My results show that hypoxia inhibits both growth factor 
and amino acids dependent mTORC1 activation.  Although I cannot rule out 
the possibility that hypoxia inhibits mTORC1 by directly affecting both 
pathways independently, it is more likely that hypoxia inhibits a common 
downstream target of both pathways.  This strongly suggests that hypoxia 
exerts its regulatory effect directly at the level of mTORC1.   
 
In summary, hypoxia inhibits the mTORC1 pathway post-
translationally at the level of mTORC1 directly.  This inhibition is likely 
independent of known oxygen sensors which includes dioxygenases such as 
PHDs.  Therefore, I tested the possibility that a different family of oxygen 
dependent enzymes is involved in mTORC1 regulation and found evidence 
that heme containing proteins might be novel regulators of mTORC1.  This 
family of proteins includes respiratory cytochromes, gas sensors, P450 




cyclases and even transcription factors.  Using general inhibitors, I obtained 
evidence that mTORC1 activity is inhibited in the absence of active heme 
containing proteins.  This inhibition is likely not via oxidative phosphorylation 
because treatment with KCN, an inhibitor of cytochrome c oxidase, did not 
inhibit mTORC1 activity, in contrast to sodium azide and GSNO treatment.  
Also, mTORC1 activity was not significantly affected by the treatment of cells 
with mitochondrial ETC inhibitors.  This is in further support that mTORC1 
regulation is independent of oxidative phosphorylation.  Identification of the 
specific mediator involved in the post-translational regulation of mTORC1 in 
hypoxia in future studies might reveal a novel drug target through which 












REDD1 (Regulated in Development and DNA Damage responses 1) is 
a negative regulator of mTORC1 in hypoxia and functions in a TSC2 
dependent manner (Brugarolas et al., 2004; Reiling and Hafen, 2004).  
REDD1 was first identified to be upregulated in response to hypoxia and DNA 
damage (Shoshani et al., 2002; Ellisen et al., 2002).  The REDD1 gene (also 
known as RTP801/Dig1/DDIT1) belongs to a family of genes that includes its 
paralog REDD2 (TRP801L/Dig2/DDIT4L) (Ellisen et al., 2002) and the 
Drosophila orthologs Scylla and Charybdis (Reiling and Hafen, 2004).  
REDD1 is ubiquitously expressed and is found in most adult tissues, however 
the expression of REDD2 is highly restricted (Reiling and Hafen, 2004; 
Ellisen et al., 2002; Shoshani et al., 2002).  REDD1 is upregulated through 
transcriptional mechanisms in response to different stress stimuli such as DNA 
damage, ER stress, hypoxia, serum deprivation, glucocorticoid-, hydrogen 
peroxide-, dexamethasone-treatment (Ellisen et al., 2002; Shoshani et al., 2002; 
Lee et al., 2004; Whitney, Jefferson and Kimball, 2009; Wang et al., 2003).  
Moreover, the induction of REDD1 is mediated by different transcription 
factors including p53, p63, ATF4, Sp1 and HIF1, indicating that REDD1 is an 
important regulator in response to diverse stress conditions (Ellisen et al., 






REDD1 is a highly unstable protein. The REDD1 protein half-life has 
been reported to be between 5-7 mins (Kimball et al., 2008; Katiyar et al., 
2009).  This indicates that REDD1 is also subject to stringent post-
translational control.  However, as there are no known structural domains or 
functional motifs present in REDD1 and not much is known about the 
regulation of REDD1 stability.  It has been reported that REDD1 is degraded 
by the Cul4a (Cullin 4a)-DDB1 (DNA damage-binding protein 1)-ROC1 
(regulator of cullins 1)--TRCP ubiquitin E3 ligase complex through a 
phosphorylation dependent mechanism mediated by glycogen synthase kinase 
3 (GSK3) (Katiyar et al., 2009).  However, it is not known how the stability 
of REDD1 is regulated in response to physiological signals. 
 
 In this study, I identified a novel mTORC1-REDD1 feedback loop 
whereby mTORC1 regulates REDD1 protein stability. Furthermore, I 
observed that REDD1 stability is not regulated by GSK3β dependent 
phosphorylation and that REDD1 is not ubiquitinated by Cul4a or other Cullin 








4.2.1 mTORC1 regulates cellular REDD1 protein levels 
 
 I initially observed that overexpression of REDD1-V5 in HEK293 
cells led to reduced levels of endogenous REDD1 protein when compared to 
REDD1 protein in untransfected cells (Figure 63).  High levels of REDD1 are 
known to inhibit the mTORC1 pathway.  This suggested that inhibition of 
mTORC1 activity may be responsible for the downregulation of the REDD1 
protein levels.  I therefore tested if inhibition of the mTORC1 pathway with 
rapamycin causes a similar downregulation of the REDD1 protein.  Indeed, 
treatment of cells with rapamycin resulted in a marked reduction in REDD1 
protein abundance (Figure 64).  This effect was also observed in a different 
cell line, HepG2 (Figure 65).  Importantly, when cells were treated with a 
different mTORC1 inhibitor PP242, REDD1 protein levels were also 
markedly reduced (Figure 65).  This indicates that the effect of mTORC1 
inhibition on REDD1 is specific. 
 
Figure 63.  Overexpression of REDD1-V5 led 
to reduced levels of endogenous REDD1 
protein. REDD1-V5 pcDNA3 (0.4 μg) was 
transfected in HEK293 cells for 3 days 
followed by cell lysis and detection of 
endogenous REDD1 proteins by Western 















Figure 64.  Rapamycin treatment resulted in marked reduction in REDD1 
protein abundance. HEK293 cells with and without the transfection of 
REDD1-V5 pcDNA3 (0.15 μg) were treated with 20 nM rapamycin for 4 or 
36 hours followed by cell lysis.  
 
 
Figure 65.  Rapamycin and PP242 
treatment led to marked reduction in 
REDD1 protein levels.  HepG2 cells were 
treated with 20 mM rapamycin or 2 μM 




To test if the mTORC1 regulation of REDD1 is due to a decrease in 
transcription, I also determined the effect of mTORC1 inhibition on 
transfected REDD1 levels as the expression of REDD1-V5 pcDNA3 plasmid 
is driven by a constitutively active CMV promoter.  Transfected REDD1 
levels also decreased with rapamycin treatment (Figure 64).  This indicates 
that the mTORC1 regulation of REDD1 is independent of transcription and is 
likely a result of altered REDD1 degradation.   
 
One of the major downstream targets of mTORC1 is p70 S6 kinase 
(p70S6K).  To determine the involvement of S6K1 in the feedback regulation 






residue mutated to alanine) in HEK293 cells.  Interestingly, this led to reduced 
REDD1 expression levels and hence mimicked the effect of rapamycin (Figure 
66).  On the other hand, mutation of the threonine 389 residue to aspartate to 
mimic phosphorylation resulted in an increase in the co-transfected REDD1 
levels (Figure 67).  This indicates that active mTORC1 increases REDD1 
levels via p70S6K.  
 
 
Figure 66.  Inactive p70S6K mutant led 
to reduced REDD1 protein abundance. 
REDD1-V5 pcDNA3 (0.1 μg) was co-
transfected with 0.2 μg empty pcDNA3 
or p70S6K T389A for 3 days followed 
by cell lysis.   
 
 
Figure 67.  Active p70S6K mutant 
increases REDD1 protein 
abundance.  HEK293 cells were 
transfected with REDD1-V5 
pcDNA3 (0.15 μg) and/or of 0.35 
μg p70S6K T389D in the indicated 
combinations for 3 days and 
treated with 20 nM rapamycin for 
36 hours before cell lysis.  
 
To further confirm the effect of mTORC1 activity on REDD1 protein 




 mouse embryonic fibroblasts 
(MEFs).  These cells have differential mTORC1 activities due to the presence 
or absence of the mTORC1 upstream negative regulator TSC2.  In the TSC2
-/-
 
MEFs where mTORC1 is constitutively active, REDD1 levels are much 
higher compared to TSC2
+/+
 cells (Figure 68).  Thus, consistent with my 







abundance.  As expected from the results in HEK293 cells, treatment with the 
mTORC1 inhibitors rapamycin or PP242 reduced REDD1 expression 




 MEFs (Figure 68).  Taken together, 
















 cells were treated with rapamycin (40 nM) or PP242 (2 μM) for 






4.2.2 mTORC1 regulates REDD1 protein stability 
 
I next determined whether the downregulation of REDD1 upon 
mTORC1 inhibition is due to increased protein turnover.  To this end, I treated 
cells with the protein synthesis inhibitor cycloheximide in the presence or 
absence of rapamycin and determined protein degradation rates.  REDD1 half-
life was shorter when mTORC1 was inhibited with rapamycin (Figure 69).  In 
control cells, REDD1 protein decreased by 27% after 15 mins of 
cycloheximide treatment.  In contrast, in the presence of rapamycin, the 
decrease in REDD1 protein during the same time period was much more 
dramatic (70%).  Similarly, inhibition of mTORC1 with treatment of PP242 










Figure 69.  mTORC1 inhibition with rapamycin treatment increases REDD1 
degradation.  HEK293 cells were pretreated with 20 nM rapamycin for 1 hour 
followed by treatment with cycloheximide (40 μM) and cell lysis at the 










Figure 70. mTORC1 inhibition with PP242 treatment increases REDD1 
degradation.  HEK392 cells cells were pretreated with 2 μM PP242 for 4 hour 
followed by treatment with cycloheximide (40 μM) and cell lysis at the 
indicated time points. 
 
The decrease in REDD1 levels upon treatment with mTORC1 
inhibitors rapamycin and PP242 treatment was reversed with addition of 
proteasome inhibitor, MG-132 (Figure 71).  This indicates that upon mTORC1 
inhibition REDD1 is degraded in a 26S proteasome dependent manner. 
Figure 71. REDD1 degradation induced by mTORC1 inhibition was reversed 
with proteasome inhibitor MG-132 treatment.  Co-treatment of rapamycin (20 
nM) or PP242 (2 μM) with MLN4924 (2 μM) or MG-132 (20 μM) were 









When comparing the effects of rapamycin and PP242, it was noted that 
the decrease in REDD1 protein levels upon PP242 treatment was much 
stronger compared to rapamycin treatment for both 4 and 24 hours (Figure 72).  
Yet, both PP242 and rapamycin inhibited mTORC1 activity markedly, as 
shown by the absence of p70S6K phosphorylation.  Furthermore, it was found 
that a pronounced effect of PP242 treatment on REDD1 protein stability could 
only be observed with endogenous, but not transfected REDD1 (Figure 72).  
These results suggested that PP242 exerts additional effects on REDD1.  The 
differential effect of PP242 on endogenous and transfected REDD1 could be 
explained by the fact that their transcription is driven from different promoters 
(endogenous REDD1 promoter versus CMV promoter).  We therefore 
hypothesized that PP242 may regulate REDD1 transcription, in addition to 
regulating REDD1 protein stability. 
 
 
Figure 72. mTORC1 inhibition with rapamycin and PP242 treatment 
increases REDD1 degradation.  HEK392 cells were transfected with 0.4 μg 
REDD1-V5 pcDNA3 followed by treatment with 20 nM rapamycin or 2 μM 







To test the effect of PP242 on REDD1 transcription, I performed 
reporter assays using two different REDD1 promoter constructs containing 
two fragments of the REDD1 promoter, a 0.6 kb fragment immediately 
upstream of exon 1 and a 3 kb fragment further upstream (Figure 73A).  If 
PP242 treatment affects REDD1 expression at the promoter region, we would 
expect to see a reduction in luciferase signal intensity.  When testing the effect 
of rapamycin, it was observed that both REDD1 promoter constructs showed 
reduced promoter activity (Figure 73B).  This suggests that rapamycin may 
regulate the entire 3.6 kb REDD1 promoter region.  However, a more likely 
interpretation would be that mTORC1 inhibition with rapamycin exerts a non-
specific effect on REDD1 as it may be unlikely that rapamycin regulates 
REDD1 expression at two different promoter regions.  On the other hand, 
similar to rapamycin treatment, treatment of PP242 led to a decrease in 
promoter activity for the 0.6 kb REDD1 promoter construct (Figure 73B).  
However, PP242 treatment resulted in a much more dramatic decrease in 
REDD1 promoter activity in the 3 kb REDD1 promoter construct (Figure 
73B).  This result suggests that PP242 has a specific inhibitory effect on 
REDD1 transcription mediated through the 3 kb promoter region upstream of 
exon 1.  Hence, this may be the reason why PP242 treatment led only to a 
small decrease in the CMV promoter driven REDD1-V5 pcDNA3 expression 
as the effect of PP242 requires REDD1 promoter region. Thus, in addition to 
mTORC1 inhibition, PP242 may have additional effect on REDD1 promoter 
activity.  These results suggest that PP242 affects REDD1 expression in two 






















Figure 73.  PP242 affects REDD1 promoter.  (A) Schematic diagram to show 
the location of the 3 kb and 0.6 kb REDD1 promoter in the luciferase reporter 
constructs used.  The three white boxes are the three exons encoding REDD1.  
This diagram was adapted from Ellisen et al., 2002.  (B) HEK293 cells were 
transfected with 3 kb REDD1 promoter pGL-3 basic (0.25 g) or 0.6 kb 
REDD1 promoter pGL-3 basic (0.25 g) constructs for 30 hours.  Six hours 
after transfection, cells were treated with rapamycin (40 nM) or PP242 (2 μM) 
treatment for 24 hours followed by reporter assay analysis using Steady-Glo 






4.2.3 REDD1 is ubiquitinated  
 
 To characterize how REDD1 is degraded, I first tested if REDD1 is 
ubiquitinated in vitro.  Polyubiquitination is an important post-translational 
modification that targets proteins for degradation through the proteasomal 
pathway.  It can be observed that REDD1 is polyubiquitinated in vitro as 
shown by the high molecular weight smear in lane 4 (Figure 74).  This 
suggests that REDD1 degradation is regulated by the ubiquitin-dependent 
proteasomal degradation pathway.   
 
 
Figure 74. REDD1 is 
ubiquitinated.  
HEK293 cells were 
transfected with 1.5 
g REDD1-V5 
pcDNA3 in 60 mm 
tissue culture plates 
for 3 days, followed 
by cell lysis and 
immunoprecipitation 
with V5 antibody.  In 
vitro ubiquitination 
assay was performed 













4.2.4 Lysine residues are not involved in REDD1 ubiquitination 
 
 Ubiquitination of protein occurs with the attachment of ubiquitin to 
lysine residues on substrate proteins.  Hence, to understand the ubiquitination 
and degradation of REDD1, I mutated lysine residues on REDD1 to alanine.  
There are a total of 6 lysine residues on REDD1 (K129, K155, K188, K218, 
K219 and K220) (Figure 75A).  Mutation of different combinations of lysine 
residues to alanine did not stabilize REDD1 as treatment with MG-132 
resulted in a similar accumulation of wild type REDD1 and REDD1 mutant 
proteins (Figure 75B).  Importantly, when all 6 lysine residues were mutated 
to alanines in the K(0) mutant, REDD1 protein remained unstable (Figure 
75B).  Treatment with MG-132 led to an increase in REDD1 K(0) protein 
levels (Figure 75B) and increased in the half-life of REDD1 K(0) mutants 
(Figure 76).  These results showed that the REDD1 K(0) mutant is degraded 
by the 26S proteasome even in the absence of lysine residues.  Furthermore, 
the half-life of the K(0) mutant was not significantly longer compared to 
controls (Figure 77).  Taken together, these results suggest that REDD1 
ubiquitination is independent of lysine residues.  Several proteins including 
p21, MyoD and Id2 proteins have been reported to be degraded via N-terminal 
ubiquitination whereby the first ubiquitin is attached to the -NH2 group of 
the N-terminal residue (Bloom et al., 2003; Breitschopf et al., 1998; Fajerman, 
Schwartz and Ciechanover, 2004).  It would be interesting to test if REDD1 is 






Figure 75.  REDD1 lysine mutants are degraded by 26S proteasome.  (A) 
Schematic diagram to show the lysine residues on REDD1.  (B) HEK293 cells 
were transfected with 0.4 g REDD1 wild-type (wt) or REDD1 lysine mutants 
(with lysine residues mutated to alanine) for 3 days followed by MG-132 (20 
μM) treatment for 6 hours and cell lysis.  KKK is a combination of K218, 
K219 and K220.  K(0) is a lysine-less mutant with all 6 lysine residues 
mutated to alanine.   
 
Figure 76. REDD1 protein stability is independent of its lysine residues.  
HEK293 cells were transfected with 0.4 g REDD1 K(0) mutant pcDNA3 for 
3 days followed by MG-132 (20 μM) treatment for 4 hours.  After that, 
cycloheximide (40 μM) treatment was performed and cells were lysed at 







Figure 77. REDD1 protein stability is independent of its lysine residues.  
HEK293 cells were transfected with 0.4 g REDD1 wild type or REDD1 K(0) 
mutant pcDNA3 for 3 days followed by cycloheximide (40 μM) treatment and 

















4.2.5 REDD1 truncation mutants do not reveal any degradation motifs or 
sequences  
 
 Next, to characterize important degradation motifs or sequences in 
REDD1, I performed deletion analyses.  First I aligned the REDD1 protein 
sequence with that of its ortholog, REDD2 (Figure 78).  REDD1 and REDD2 
are both inhibitors of mTORC1 and share about 50% sequence identity to each 
other but show little homology to other known proteins (Brugarolas et al., 
2004; Corradetti et al., 2004).  As REDD1 and REDD2 may be regulated in a 
similar manner, I truncated the REDD1 protein based on regions with the 
highest similarities with REDD2.  Truncations of the C-terminal ends of 
REDD1 did not stabilize REDD1 (Figure 79).  Similarly, when the N-terminal 
end was truncated, REDD1 protein remained unstable as indicated by the 
accumulation of truncated REDD1 with MG-132 treatment (Figure 80). These 
results suggest that REDD1 degradation motifs could be located at both the C- 
and N-terminal ends.    
Figure 78. Alignment of REDD1 and REDD2 protein sequences.  Boxed 
sequences indicate GSK3 phosphorylation sites and AMP kinase recognition 






Figure 79. REDD1 C-terminal end truncations did not stabilize REDD1 
protein.  HEK293 cells were transfected with 0.4 g REDD1 (full length or 
truncated mutants) for 3 days followed by MG-132 (20 μM) treatment for 6 
hours and cell lysis.  REDD1-V5 (1-202) mutant has its AMPK motif 
truncated whereas both AMPK motif and GSK3 sites are truncated in the 
REDD1-V5 (1-162) mutant. REDD1-V5 (1-132) is the shortest mutant with 











Figure 80. REDD1 N- and C-terminal end truncations did not stabilize 
REDD1 protein.  HEK293 cells were transfected with 0.4 g REDD1 (full 
length or truncated mutants) for 3 days followed by MG-132 (20 μM) 
treatment for 6 hours and cell lysis.  REDD1-V5 (129-233) mutant is the C-









4.2.6 iTRAQ analysis of REDD1 did not reveal potential binding proteins 
that could mediate REDD1 ubiquitination and degradation  
 
 iTRAQ (isobaric tags for relative and absolute quantitation) is a mass 
spectrometry based approach for relative quantification of proteins.  This 
technique allows quantitation of differences in protein amount between 
different samples by tagging peptides with iTRAQ isotope followed by 
peptide separation with 2D-liquid chromatography.  In my project, a 4-plex 
analysis was used and 4 different iTRAQ reagents were used to label the 4 
samples.  Identical peptides obtained from the different samples can be 
identified based on the iTRAQ isotopes labeling and quantitation of the 
amount is analyzed from the signal intensity ratios of labels.  In the 
experiment, I used lysate from HEK293 cells transfected with FLAG-REDD1 
and untransfected HEK293 cells as control.  The FLAG-REDD1 protein was 
immunoprecipitated using FLAG agarose.  After that, FLAG-REDD1 protein 
complexes were eluted with the addition of acetic acid followed by 
neutralizing buffer for iTRAQ analysis (see Materials and Methods for details).  
The samples were then sent for iTRAQ analysis by a commercial lab at UVic 
Genome BC Proteomics Centre.   
 
The iTRAQ analysis revealed a significant number of potential 
REDD1 binding proteins that were enriched in the FLAG-REDD1 transfected 
compared to the untransfected sample.  The potential REDD1 interacting 
proteins included two proteins that are known to be involved in the ubiquitin-




dissociated 1 (CAND1) proteins.  Cullin 2 forms an E3 ligase that utilizes 
Elongin B and C as adaptor proteins to recruit substrate receptors.  Hence, to 
test if Cullin 2 plays a role in the regulation of REDD1 protein stability, 
siRNA mediated silencing of the Cullin 2 adaptor protein, Elongin C, was 
performed.  HIF1, a substrate of Cullin 2, is stabilizes with knockdown of 
Elongin C (Figure 81).  However, no significant increase in REDD1 protein 
level was observed (Figure 81).  This result indicates that Cullin 2 is not 
involved in the regulation of REDD1 protein stability.   
 
Figure 81. REDD1 stability is independent of 
Elongin C and Cul2 E3 Ligase. HEK293 cells 
were transfected with 20 nM control or Elongin 






CAND1 is a regulatory protein that interferes with the assembly of the 
SKP1-Cul1-F-box (SCF) and other Cullin E3 ubiquitin ligase complexes and 
hence regulates the activity of Cullin E3 ligases.  Therefore, we were 
interested to find out if REDD1 is regulated by CAND1.  Knockdown of 
CAND1 led to a decrease in REDD1 protein levels (Figure 82).  However, the 
decrease in REDD1 protein levels was not correlated with CAND1 expression 
as the first siRNA, which was more effective in silencing, did not decrease 





This result suggests that the regulation of REDD1 protein stability is 
independent of CAND1. 
 
 
Figure 82.  REDD1 protein stability 
is independent of CAND1.  HEK293 
cells were transfected with 20 nM 
control or CAND1 siRNAs for 3 days 







4.2.7 Regulation of REDD1 by the HUWE1 E3 ubiquitin ligase  
 
To identify the E3 ligase involved in the REDD1 degradation upon 
mTORC1 inhibition, I tested a number of candidates.  Interestingly, while 
performing experiments to study the regulation of CDC6 protein stability (see 
5.2.5), I observed that the knockdown of the E3 ubiquitin ligase HUWE1 
caused an increase in REDD1 steady state levels (Figure 83 and 84).  This 
effect was not due to changes in mTORC1 activity, as indicated by the 
unaltered levels of p70S6K phosphorylation (Figure 84).  An increase in the 
steady state level of the known HUWE1 substrate Mcl-1 served as a positive 
control (Figure 84).  I also observed that when mTORC1 activity was 
inhibited with rapamycin or PP242, REDD1 protein levels were higher in cells 
transfected with HUWE1 siRNA compared to control cells (Figure 84).  
However, when HUWE1 was immunoprecipitated, REDD1 protein was not 
detected indicating that the two proteins do not interact (Figure 85).  As the 
enrichment of HUWE1 in the immunoprecipitate was very weak, a reciprocal 
IP was performed whereby REDD1 was immunoprecipitated.  Again, no 
interaction was observed between HUWE1 and REDD1 (Figure 86).  
Furthermore, the increase in REDD1 protein levels upon HUWE1 knockdown 
was similar in mTOR inhibiter treated and untreated cells  (Figure 84).  Based 
on these results, I concluded that HUWE1 is not involved in the degradation of 


















Figure 83.  REDD1 protein stability is regulated by HUWE1 ubiquitin ligase. 
HEK293 cells were transfected with 20 nM negative control siRNA or 
HUWE1-1 or -2 siRNAs in the indicated combinations for 3 days and MG-132 













Figure 84.  REDD1 protein stability is regulated by HUWE1 ubiquitin ligase. 
HEK293 cells were transfected with 20 nM control or HUWE1 siRNAs for 3 
days and rapamycin (40 nM) or PP242 (2 μM) were added to cells for 8 hours 










Figure 85. REDD1 does not interact with HUWE1.  HEK293 cells were 
grown in 60 mm tissue culture plates for 4 days followed by cell lysis and 
immunoprecipitation with HUWE1 antibody as described in Materials and 
Methods.  
Figure 86. HUWE1 does not interact with REDD1.  HEK293 cells were 
transfected with the full-length and truncation mutants of REDD1 pcDNA3 
(1.5 g for all REDD1-V5 pcDNA3 except for REDD1-V5 (129-233) 
pcDNA3 at 2 g) in 60 mm tissue culture plates for 3 days followed by cell 







Given that HUWE1 knockdown caused an increase in the steady state 
levels of the REDD1 protein, I next tested whether the HUWE1 is involved in 
the basal turnover of REDD1.  I measured the protein half-life using 
cycloheximide chase with two different HUWE1 siRNAs.  However, with 
both siRNAs there was no significant change in the half-life of REDD1 in 
cells with HUWE1 knockdown compared to controls (Figures 87 A and B).  
This suggests that HUWE1 regulates REDD1 via a mechanism that is 
independent of protein degradation.   
Figure 87.  REDD1 protein stability is not regulated by HUWE1 ubiquitin 
ligase. (A,B) HEK293 cells were transfected with 20 nM negative control or 
HUWE1-1 (A) or -2 (B) siRNAs for 3 days followed by cycloheximide (40 






4.2.8 REDD1 protein stability is not regulated by Cullin E3 ubiquitin 
ligases  
 
Cullin E3 ubiquitin ligases constitute approximately half of the cellular 
E3 ligases.  Furthermore, Cullin 4 E3 ligase has previously been implicated in 
regulating the basal turnover of REDD1.  I therefore determined whether the 
family of Cullin E3 ligases is involved in REDD1 degradation upon mTORC1 
inhibition.  This was tested using MLN4924, an inhibitor of Nedd8 E1 
activating enzyme which inhibits all cullin E3 ligases (Soucy et al., 2009).  I 
observed that MLN4924 did not reverse the degradation of REDD1 upon 
treatment of cells with the mTORC1 inhibitors rapamycin or PP242 (Figure 
71).  Furthermore, unlike the proteasome inhibitor MG-132, MLN4924 also 
had no effect on the basal protein levels of REDD1 (Figure 71).  This result 
was surprising given the previous report of Cullin 4 dependent regulation of 
REDD1 protein stability [11].  Hence, in further studies, I characterized the 
involvement of Cullin E3 ligases in the regulation of REDD1 stability in detail.   
 
As an alternative approach to using MLN4924, I utilized a genetic 
approach by expressing the dominant negative C111S mutant of the Ubc12 
Nedd8 E2 conjugating enzyme.  A HEK293 cell line in which dominant-
negative Ubc12 (dnUbc12) was stably transfected and expressed under control 
of a tetracycline-inducible promoter was used (Chew et al., 2007).  The 
dnUbc12 cells have a defective neddylation pathway and this leads to the 
inactivation of the Cullin RING E3 ubiquitin ligases.  Similar to MLN4924 




endogenous and transfected REDD1 proteins (Figures 88 and 89).  
Overexpression of dnUbc12 caused a dramatic increase in the known Cullin 
E3 ligase substrate p27 which was even more pronounced compared to the 
proteasome inhibitor MG-132 (Figure 89).  This shows that REDD1 steady 
state level is not regulated by Cullin ubiquitin ligases.  I subsequently 
performed experiments to determine the effect of pharmacological and genetic 
inhibition of Cullin E3 ligases on the REDD1 protein half-life.  I observed no 
difference in the half-life of both endogenous and transfected REDD1 when 
HEK293 cells were treated with MLN4924 (Figures 90 A and B) or when 
dnUbc12 expression was induced with tetracycline (Figure 91).  In contrast, as 
expected, p27 was stabilized with both inhibitors.  These results indicate that 






Figure 88. REDD1 is not regulated by Cullin E3 Ubiquitin ligases. HEK293 
cells stably expressing tetracycline inducible dnUbc12-HA were induced with 
1 μg/ml tetracycline for 24 hours or treated with 3 μM MLN4924 or 20 μM 
MG-132 for 8 hours followed by cell lysis.  
 
 
Figure 89. REDD1 is not regulated by 
Cullin E3 Ubiquitin ligases. HEK293 cells 
stably expressing tetracycline inducible 
dnUbc12-HA were transfected with 
REDD1-V5 pcDNA3 (0.3 μg) and induced 
with 1 μg/ml tetracycline for 24 hours or 
treated with 20 μM MG-132 for 8 hours 
followed by cell lysis 







Figure 90. REDD1 is not regulated by Cullin E3 Ubiquitin ligases. (A,B)  
Untransfected HEK293 (A) or HEK293 transfected with REDD1-V5 pcDNA3 
(0.3 μg) (B) were pre-treated with 3 μM MLN4924 followed by 
cycloheximide (40 μM) treatment and cell lysis at the indicated time points.   
 
Figure 91. REDD1 is not regulated by Cullin E3 Ubiquitin ligases.  HEK293 
cells stably expressing tetracycline inducible dnUbc12-HA were induced with 
1 μg/ml tetracycline for 24 hours followed by cycloheximide (40 μM) 







4.2.9 Both Cul4a and phosphorylation of REDD1 by GSK3β are not 
involved in basal REDD1 protein turnover 
 
It has been reported that REDD1 degradation is mediated by the Cul4a 
E3 ubiquitin ligase complex and that this in turn is dependent on REDD1 
phosphorylation at Thr23 and Thr25 sites by GSK3β.  Therefore, to confirm 
this, I overexpressed a tetracycline inducible dominant negative Cul4a-V5 
plasmid (dnCul4a, amino acids 1–439) in HEK293 cells (Chew and Hagen, 
2007).  dnCul4a lacks the C-terminal half of the Cul4a protein.  Hence, 
dnCul4a is able to interact with substrate proteins, but unable to recruit the 
ubiquitin-charged E2 ubiquitin conjugating enzyme. As a result, dnCul4a 
sequesters substrates in inactive complexes and inhibits their ubiquitination 
and degradation.  If REDD1 is a substrate of Cul4a, an increase in REDD1 
protein expression would be expected upon induction of dnCul4a.  However, it 
was observed that REDD1 levels were not affected by dnCul4a induction 
(Figure 92).  To confirm that dnCul4a overexpression and induction was able 
to inhibit Cul4a function, I demonstrated that dnCul4a markedly reduced the 
neddylation levels of coexpressed full length Cul4a (Figure 92).  Nedd8 
modification (neddylation) of cullin proteins is required for the function of all 
cullin E3 ligases.  Cullin neddylation is dependent on the binding of substrate 
proteins (Chew and Hagen, 2007).  Hence, the markedly reduced neddylation 
of full length Cul4a indicates that substrate binding is inhibited.  The dnCul4a 






Figure 92.  REDD1 is not 
degraded by Cul4a E3 
Ubiquitin Ligase. HEK293 
cells were transfected with 
empty vector or tetracycline 
inducible dnCul4a-V5 
pcDNA4/TO (1 μg) and 
Cul4A-V5 pcDNA3 (0.03 μg) 
followed by tetracycline (1 
μg/ml) induction for 24 hours 
and cell lysis. 
 
 
I also used siRNA mediated silencing of Cul4a to confirm the results 
obtained with the dnCul4a cell line.  I used two different siRNA 
oligonucleotides and Cul4a siRNA-2 proved more effective (Figure 93).  I 
observed that knockdown of Cul4a did not affect REDD1 expression (Figure 
94).  As expected, the level of the Cul4a-DDB1-DDB2 substrate p27 level was 
markedly increased with Cul4a siRNA-2.  In conclusion, Cul4a is unlikely to 
be involved in the regulation of REDD1 protein stability. 
 
Figure 93. Cul4a siRNA 
decreased Cul4a expression.  
HEK293 cells were transfected 
with 0.5 μg Cul4a-V5 pcDNA3 
for 15 hours followed by 
transfection of 20 nM control or 
Cul4a siRNAs to determine 





Figure 94.  REDD1 is not 
degraded by Cul4a E3 Ubiquitin 
Ligase.  HEK293 cells were 
transfected with 20 nM control or 
Cul4a siRNAs for 3 days followed 








It has been reported that GSK3β phosphorylates REDD1 at residues 
Thr23 and Thr25, resulting in REDD1 recruitment to the Cullin 4a-β-Trcp E3 
ligase complex.  To confirm involvement of these threonine residues in the 
regulation of REDD1 protein stability, I mutated both Thr23 and Thr25 to 
alanines.  These mutations would be expected to stabilize REDD1 protein.  
However, I did not observe any significant difference in the stability of 
REDD1 mutant compared to controls (Figure 95).  Addition of proteasome 
inhibitor caused a similar increase in wild type and T23A/T25A mutant 
REDD1 protein levels, suggesting that the phosphorylation sites are not 
important for the regulation of REDD1 protein stability.   Furthermore, 
mutation of the threonine 23 and 25 residues to aspartate to mimic 
phosphorylation also did not have any effect on REDD1 stability (Figure 95).  
 
 
Figure 95.  REDD1 is not degraded via phosphorylation by GSK3β at Thr23 
and Thr25.  REDD1-V5 pcDNA3 wild type, T23A T25A or T23D T25D 
plasmids (0.4 μg) were transfected in HEK293 cells for 3 days and treated 
with 20 μM MG-132 for 6 hours followed by cell lysis.  
 
To further confirm that GSK3β does not regulate REDD1 protein 
levels, two different inhibitors of GSK3β were added to HEK293 cells, lithium 
chloride and GSK3 inhibitor IX.  Both inhibitors blocked the activity of 
GSK3β, as indicated by the marked decrease in the phosphorylation of the 





increase REDD1 stability. However, I did not observe any significant 
difference in REDD1 expression levels upon addition of the GSK3β inhibitors 
(Figure 96).  Moreover, overexpression of GSK3β did not result in decreased 
REDD1 stability despite a dramatic increase in GSK3β expression compared 
to untransfected cells (Figure 97).  I also tested whether incubation of REDD1 
with recombinant GSK3 causes a band shift indicative of phosphorylation.  Of 
note, Katiyar et al. reported that GSK3β dependent phosphorylation of 
REDD1 causes a faster migration in SDS gels (Katiyar et al., 2009).  However, 
no change in electrophoretic mobility was detected, whereas the reported 
GSK3β substrate FRAT1 displayed the expected band shift (Figure 98). Taken 
together, my results suggest that both basal and mTORC1 regulated REDD1 
degradation is mediated via a novel mechanism that does not involve Cullin 






Figure 96.  REDD1 degradation 
is independent of GSK3β. 
HEK293 cells were treated with 
30 mM LiCl or GSK3 inhibitor 
IX (5 μM or 10 μM) for 20 hours 












Figure 97. REDD1 degradation is 
independent of GSK3β.  HEK293 
cells were co-transfected with 
REDD1-V5 pcDNA3 (0.2 μg) and 
GSK3β pcDNA3 (0.3 μg) or empty 
pcDNA3 (0.3 μg) for 3 days followed 
by MG-132 (20 μM) treatment for 6 
hours followed by cell lysis.   
 
Figure 98. REDD1 degradation is independent of GSK3β.  HEK293 cells 
were transfected with 3 μg FLAG-REDD1 or FLAG-FRAT1 for 3 days 
followed by cell lysis and FLAG immunoprecipitation.  In vitro 
phosphorylation of REDD1 and FRAT1 was carried out as described in 








REDD1 is an important negative regulator of mTORC1 in response to 
stress.  In this study, I have shown that mTORC1 in turn also regulates 
REDD1. mTORC1 dependent regulation of REDD1 is at the level of the 
REDD1 protein stability.  Inhibition of mTORC1 using the small molecules 
rapamycin and PP242 or by overexpressing REDD1 led to reduced REDD1 
protein stability and a consequent decrease in REDD1 expression.  This 
mTORC1-REDD1 feedback loop would limit the inhibitory action of REDD1 
on mTORC1 (Figure 99).  The physiological significance of the mTORC1-
REDD1 feedback mechanism is currently not clear and requires further study.  
However, my finding highlights that in addition to the extensive 
transcriptional control of REDD1, the REDD1 protein is also subject to 









Figure 99.  The mTORC1-REDD1 limits the inhibitory action of REDD1 on 
mTORC1.  When mTORC1 is active, ubiquitination and proteasome 
dependent degradation of REDD1 is inhibited (left panel).  Under conditions 
of hypoxia and other stress stimuli, REDD1 is transcriptionally induced, 
leading to mTORC1 inhibition.  As a consequence, REDD1 ubiquitination and 
degradation is no longer restricted by mTORC1 (right panel).  This mTORC1-






In further experiments, I studied the mechanism through which 
REDD1 stability is regulated.  I found that REDD1 degradation in response to 
mTORC1 inhibition is proteasome dependent.  However, contrary to a 
previous report (Katiyar et al., 2009), I observed that mTORC1 protein 
stability is not controlled by the Cul4a E3 ubiquitin ligase.  The discrepancy 
between the reported Cul4a dependent regulation of REDD1 and my results is 
unlikely to be due to differences in cell type as both studies used HEK293 
cells.  Furthermore, I was unable to confirm the role of GSK3β in targeting 
REDD1 for ubiquitination.  Thus, I found that mutation of the reported GSK3β 
phosphorylation sites in REDD1 to alanine or aspartate did not affect REDD1 
protein levels.  Similarly, inhibition of GSK3β with two different inhibitors 
and overexpression of GSK3β were without effect on REDD1 protein 
expression.  Furthermore, no band shift was observed upon incubation of 
REDD1 with GSK3β in vitro.  It should be noted that mutation of serine or 
threonine residues to aspartate does not always have phospho-mimetic effects 
and phosphorylation events do not cause a lower mobility in every instance.  
Despite these limitations, when taking all of my findings together, there is 
strong evidence against a role of GSK3β in the regulation of REDD1 protein 
stability. 
 
My results suggest that an alternative E3 ligase is responsible for both 
basal REDD1 ubiquitination and ubiquitination that is induced upon mTORC1 
inhibition.  Using pharmacological and genetic inhibitory approaches, I have 
ruled out any role for members of the Cullin RING E3 ligase family, which 




knockdown of the HUWE1 E3 ubiquitin ligase resulted in increased REDD1 
protein steady state levels, my further studies indicated that this effect is not 
due to an effect of HUWE1 on REDD1 protein stability.  Hence, the identity 
of the E3 ligase that mediates basal REDD1 ubiquitination and ubiquitination 
upon mTORC1 inhibition is currently unknown.  Identification of this E3 
ligase is important as this ligase may be a unique drug target for specific 






5.0 Destabilization of CDC6 upon DNA damage is dependent on 




 Cell division cycle 6 (CDC6) is an essential regulator of DNA 
replication in eukaryotic cells.  CDC6 functions as an important component of 
the pre-replication complex (preRC). In addition to CDC6, the preRC is 
composed of the origin recognition complex (ORC) as well as Cdt1.  The 
preRC is responsible for the stable loading of the minichromosome 
maintenance complex (MCM) onto origins of replication (Liang and Stillman, 
1997; Donovan et al., 1997; Tanaka, Knapp and Nasmyth, 1997).  The preRC 
is formed during the initiation step of DNA replication.  The assembly of the 
preRC is one of the most highly regulated events during DNA replication.  
Tight regulation of preRC assembly is important to ensure that sufficient 
preRCs are formed during G1 to promote replication.  Furthermore, it is also 
crucial that new preRCs are not assembled after cells enter S phase to prevent 
rereplication (Archambault et al., 2005; Vaziri et al., 2003; Melixetian et al., 
2004; Zhu, Chen and Dutta, 2004).  One important mechanism of preRC 
regulation is the cell cycle dependent control of CDC6 protein stability.  
Furthermore, DNA replication is inhibited in hypoxia and the downregulation 
of CDC6 as a result of ATR activation in hypoxia contributes to DNA 
replication checkpoint in hypoxic cells (Martin et al., 2012).  Protein 
ubiquitination plays a critical role in the hypoxia response as it is one of the 




Mammalian CDC6 is ubiquitinated during early G1 phase by APC
Cdh1
 
in a manner dependent on both the D box and KEN box in the CDC6 protein 
(Petersen et al., 2000).  The APC
Cdh1
 mediated CDC6 ubiquitination and 
degradation is important to ensure a timely licensing of replication origins 
during G1 phase and to prevent rereplication.  There is also evidence for APC 
independent ubiquitination and degradation of the CDC6 protein.  Of 
particular significance are reports of Cullin RING E3 ligase dependent CDC6 
ubiquitination in budding yeast, fission yeast and possibly in mammalian cells 
(Chew et al., 2007; Lin et al., 2010; Soucy et al., 2009). 
 
 Cullin RING E3 ligases comprise the largest family of ubiquitin 
ligases.  They consist of several subunits, including a cullin scaffold protein, 
substrate receptor proteins that bind to the cullin N-terminus and the RING 
domain protein Rbx1, which binds to the cullin C-terminus.  Cullin RING E3 
ligases function by recruiting the substrate via a specific substrate receptor and 
the ubiquitin charged E2 ubiquitin conjugating enzyme via Rbx1.  The close 
proximity of the substrate protein and the ubiquitin charged E2 enzyme 
facilitates the transfer of ubiquitin molecules onto the substrate.  Ubiquitinated 
substrates are then targeted for degradation by the 26S proteasome.  To be 
active, Cullin E3 ubiquitin ligases require the modification of a conserved 
lysine residue in the cullin protein with the ubiquitin-like protein Nedd8. 
Neddylation of cullins is mediated via a cascade that involves the Nedd8 





In Saccharomyces cerevisiae, CDC6 is ubiquitinated in S phase by the 
SKP1-Cul1-F-box (SCF) Cullin E3 ligase whereby CDC4 functions as cullin 
substrate receptor (Drury, Perkins and Diffley, 1997).  In 
Schizosaccharomyces pombe, CDC18 (the CDC6 homolog) ubiquitination in 
S phase is mediated by the Cullin E3 ligase substrate receptor Pop1, which 
belongs to a WD-repeat family with highest homology to CDC4 (Kominami 
and Toda, 1997).  It has been hypothesized that CDC6 may also be regulated 
by Cullin E3 ligases in mammalian cells (Lin et al., 2010). 
 
In addition to being regulated during the cell cycle, CDC6 has also 
been reported to be degraded in response to DNA damage in mammalian cells 
(Duursma and Agami, 2005; Blanchard et al., 2002).  CDC6 downregulation 
during DNA damage helps to prevent replication and allow DNA repair to 
take place.  Regulation of CDC6 stability in response to DNA damage is 
mediated by the HUWE1 E3 ubiquitin ligase (Hall et al., 2007).   
 
 In this study, I determined the role of Cullin RING E3 ligases in the 
regulation of CDC6 protein stability in mammalian cells.  I found that Cullin 
E3 ligases are not involved in CDC6 degradation.  Stabilization of CDC6 upon 
inhibition of Cullin E3 ligases is a secondary consequence of a delay in cell 
cycle progression.  In addition, I found that the DNA damage inducing agent 
mitomycin C causes CDC6 protein degradation.  Mitomycin C induced CDC6 
degradation is not mediated by the known regulators of CDC6 protein stability, 
HUWE1 or APC, and is also independent of Cullin E3 ligases. Interestingly, 
my results indicate that the neddylation pathway is required for mitomycin C 






5.2.1 CDC6 protein is not markedly downregulated in hypoxia  
 
The initial aim of this part of my project was to characterize the 
regulation of CDC6 stability in hypoxia as it has been reported that CDC6 is 
downreguated in hypoxia (Martin et al., 2012).  However, my results showed 
that CDC6 protein level is not markedly downregulated in hypoxia (Figure 
100A & B).  This may be due to the different cell lines used in the study.  
Hence, the focus of my study was to determine how CDC6 stability is 
regulated. 
Figure 100.  CDC6 protein is not downregulated in hypoxia. HEK293 (A) or 
HepG2 (B) cells were incubated in 1 % O2 or treated with MG-132 (20 μM) 








5.2.2 CDC6 stability in mammalian cells is not regulated by Cul1 and 
Cul4 E3 Ligases  
 
It has been shown that treatment with MLN4924 (an investigational 
inhibitor of Nedd8 activating enzyme (NAE) that inhibits the activity of all 
Cullin E3 ligases) increases CDC6 protein expression in mammalian cells 
(Soucy et al., 2009; Lin et al., 2010).  Furthermore, inactivation of Cullin E3 
ligases by the induction of dominant negative ubc12 (dnUbc12) in HEK293 
cells stabilizes CDC6 protein (Chew et al., 2007).  To confirm these results, I 
treated various human cell lines including HEK293, Hela, HCT116 and MCF7 
cells with the proteasome inhibitor (MG-132) and the NAE inhibitor 
MLN4924.  CDC6 expression was markedly increased when cells were treated 
with the proteasome inhibitor MG-132 (Figure 101).  This indicates that 
CDC6 protein is degraded by the proteasome.  To test if Cullin E3 ligases are 
involved, I used MLN4924.  I observed that MLN4924 treatment markedly 
stabilized the known Cullin E3 ligase substrate p27, which served as a positive 
control (Figure 101).  Similarly, the CDC6 protein expression level increased 
with MLN4924 treatment suggesting that CDC6 stability may be regulated by 
Cullin E3 ligases (Figure 101).  However, the increase in CDC6 expression 
levels upon treatment with MLN4924 was only observed in HEK293, 








Figure 101.   MLN4924 treatment stabilizes CDC6 in multiple cell lines.  
HEK293, Hela, HCT116 and MCF7 cells were treated with 3 μM or 6 μM 
MLN4924 and 20 μM MG-132 for the indicated duration followed by cell 
lysis.  
 
In fission and budding yeast, Cul1 has been implicated in the 
degradation of CDC6.  Furthermore, in mammalian cells it has been shown 
that Cdt1, a member of the preRC, can be ubiquitinated by Cul1 and Cul4 E3 
ligases.  I therefore tested whether the effect of MLN4924 is a consequence of 
the inhibition of Cul1 or Cul4 based E3 ligases.  To this end, I utilized 
HEK293 cell lines stably expressing tetracycline inducible dominant negative 





Induction of dominant negative cullin 1 (dnCul1-V5, amino acids 1-452) 
strongly stabilized the Cul1 E3 ligase substrate p27 (Figure 102).  The 
increase in the p27 protein concentration is similar to that observed upon 
MLN4924 treatment.  There was also a slight increase in both endogenous and 
transfected CDC6 expression levels (Figure 102).  However, this increase was 
much less compared to the increase with MLN4924.  Therefore, it is unlikely 








Figure 102.   CDC6 protein stability is not regulated by Cul1 E3 Ligases.  
HEK293 cells stably expressing dnCul1-V5, with or without CDC6 (1 μg) 
transfection for 3 days, were induced with 1 μg/μl tetracycline for 24 hours 
before cell lysis.   
 
 
Similarly, induction of dominant negative cullin 4a (dnCul4a-V5, 
amino acids 1-439) led to an increase in the expression levels of its substrates 
p27 and p21 (Figure 103).  However, no change in CDC6 levels was observed, 
thus indicating that CDC6 protein is unlikely to be a substrate of Cul4a 
(Figure 103).  In conclusion, my results show that CDC6 protein is not a 

























Figure 103.   CDC6 protein stability is not regulated by Cul4 E3 Ligases.  
HEK293 cells stably expressing dnCul4a-V5, with or without transfection of 1 
μg CDC6 for 3 days, were induced with 1 μg/μl tetracycline for 24 hours 







5.2.3 CDC6 stabilization by MLN4924 is due to a delay in cell cycle 
progression 
 
MLN4924 has been shown to lead to accumulation of cells in S phase 
(Soucy et al., 2009).  Given that APC ubiquitinates CDC6 during early G1 
phase (Petersen et al., 2000), I therefore hypothesized that changes in the cell 
cycle profile might be responsible for the regulation of CDC6 stability.  To 
test this hypothesis, I synchronized Hela cells at the G2/M phase using 
nocodazole treatment followed by release from the nocodazole block.  
Consistent with previous reports, CDC6 protein is stable in G2/M phase as 
illustrated by high expression at t=0h in both MLN4924 treated and control 
cells (Figure 104).  Upon release, CDC6 levels decreased in control cells 
initially and accumulated at t=6h and 9h but decreased again when cells 
entered S phase at t=12h (Figure 104).  In cells treated with MLN4924, CDC6 
was also rapidly degraded during early G1 phase.  However, the subsequent 
increase in CDC6 level was markedly delayed whereby accumulation of 
CDC6 to high levels was only observed at 24 hours (Figure 104).  Cell cycle 
analyses indicated that the delayed CDC6 stabilization correlates with the 
delayed transition from G1 to S phase in MLN4924 treated cells (Figure 105).  
This result suggests that CDC6 stabilization by MLN4924 is a consequent of 








Figure 104.   MLN4924 treatment arrests cells at G1 phase.  Hela cells were 
synchronized in G2/M phase with thymidine (2 mM) treatment for 20 hours, 
followed by nocodazole (100 ng/ml) treatment for 13 hours before cell seeding 
in the presence or absence of MLN4924 (1 μM) and cell lysis at the indicated 
time points as described in Materials and Methods.   
 
Figure 105.   MLN4924 treatment arrests cells at G1 phase.  Hela were 
synchronized at G2/M phase as described, seeded in the presence of absence 
of MLN4924 (1 μM) and collected for flow cytometry analysis at the indicated 







I next confirmed that CDC6 accumulation with MLN4924 treatment at 
t=24h is due to delayed cell cycle progression and not a direct consequence of 
inhibition of Cullin E3 ligases.  Hela cells were harvested 24 hours after G2/M 
release but MLN4924 treatment was carried out either throughout the 24 hours 
or only for 4 hours before cell lysis.  If CDC6 accumulation is directly due to 
the inhibition of Cullin E3 ligase mediated CDC6 ubiquitination, 4 hour 
MLN4924 treatment would be sufficient to observe an increase in CDC6 
expression.  However, CDC6 protein accumulation was only observed upon 
prolonged treatment of MLN4924 for 24 hours while the levels of CDC6 
proteins remained low with only 4 hours MLN4924 treatment (Figure 106).  
These results strongly suggest that that the MLN4924 induced CDC6 
stabilization is a secondary consequence of a delay in G1 progression and 
accumulation of cells in G1 and S phase.  Taken together, my results indicate 
that CDC6 stability is not directly regulated by Cullin E3 ligases.  
 
Figure 106.   MLN4924 treatment arrests cells at G1 phase.  Hela cells were 
synchronized in G2/M as described and cells were lysed at t=24 hours after 
release from G2/M with treatment of MLN4924 (1 μM) for 24 hours or 
MLN4924 (1 μM), thymidine (2 mM) or nocodazole (100 ng/ml) for 4 hours 






5.2.4 Mitomycin C treatment induces CDC6 protein degradation 
 
In addition to the CDC6 protein degradation during normal cell cycle 
progression, it has been reported that CDC6 is also degraded in response to 
DNA damage.  This likely serves to prevent rereplication and promote 
checkpoint functions to block cell cycle progression when DNA damage 
occurs.  DNA damage induced CDC6 ubiquitination and degradation has been 
reported to be mediated by APC
Cdh1
 and HUWE1 E3 ligases (Hall et al., 2007; 
Blanchard et al., 2002; Duursma and Agami, 2005).  I observed that the DNA 
damaging agent mitomycin C, which causes DNA cross-linking, markedly 
reduces CDC6 stability in various cell types tested (Figure 107A and B).  
Treatment of cells with mitomycin C resulted in a shorter half-life of the 
CDC6 protein compared to no treatment (Figure 108).  In control cells, the 
half-life of the CDC6 protein is approximately 3 hours.  In contrast, treatment 
of mitomycin C resulted in a markedly shorter half-life of CDC6 protein levels 
(approximately 1 hour) (Figure 108).  Subsequently, I tested if inhibition of 
the proteasome can stabilize CDC6.  As expected, CDC6 is stabilized in the 
presence of proteasome inhibitors MG-132 and lactacystin under basal 
conditions.  Mitomycin C treatment caused a dramatic decrease in CDC6 
protein expression (Figure 109).  The decrease in CDC6 stability upon 
mitomycin C treatment was prevented by proteasome inhibition with MG-132 
and CDC6 was restored to the level in cells treated with proteasome inhibitor 
alone (Figure 109).  This indicates that the mitomycin C induced decrease in 











Figure 107.   Mitomycin C treatment induces CDC6 protein degradation.   (A) 
Structure of mitomycin C.  (B) HEK293, HCT116, MCF7 and Hela cells were 
treated with mitomycin C (10 μg/μl) for 10 hours followed by cell lysis.   
 
Figure 108.   Mitomycin C treatment induces CDC6 protein degradation.  
HEK293 cells were pre-treated with mitomycin C (10 μg/μl) or DMSO as 
control for 4 hours followed by addition of cycloheximide (40 μM) and cell 













Figure 109.   Mitomycin C treatment induces CDC6 protein degradation. 
HEK293 cells were treated with MG-132 (25 μM) or lactacystin (2.5 μM) in 















To identify the E3 ligase that regulated CDC6 protein stability with 
mitomycin C treatment, I tested different possible candidates.  Firstly, to test 
the involvement of HUWE1 E3 ligase, siRNA mediated silencing of HUWE1 
was carried out.  Cells were treated with mitomycin C or methyl methane 
sulfonate (MMS), which has been reported to induce HUWE1 mediated CDC6 
degradation.  CDC6 protein levels were only slightly higher in cells 
transfected with HUWE1 siRNAs compared to controls, despite highly 
efficient knockdown of HUWE1 (Figure 110).  Furthermore, the increase in 
CDC6 protein levels upon HUWE1 knockdown was similar in untreated and 
mitomycin C treated cells (Figure 110), indicating that HUWE1 is not 
specifically involved in the regulation of CDC6 protein stability upon 
mitomycin C treatment.  Similarly, my results suggest that MMS dependent 








Figure 110.  CDC6 degradation upon mitomycin C treatment is not mediated 
by HUWE1.  HEK293 were transfected with 20 nM control siRNA of 
HUWE1-1 or -2 siRNAs  for 3 days followed by treatment of mitomycin C 





Next, I tested if APC
Cdh1
 is involved in CDC6 downregulation upon 
mitomycin C treatment.  When Cdh1 was silenced with Cdh1 siRNA, an 
increase in CDC6 levels was observed (Figure 111).  However, knockdown of 
Cdh1 did not affect CDC6 degradation in mitomycin C treated cells (Figure 
111).  This indicated that APC
Cdh1
 is not the E3 ligase that mediates 
mitomycin C induced CDC6 degradation.  To further confirm this, I deleted 
the D box and KEN box of CDC6 which are important for the recognition by 
Cdh1 (Petersen et al., 2000) (Figure 112).  As expected, the CDC6 deletion 
mutant showed increased protein stability (Figure 113).  However, mitomycin 
C treatment markedly decreased the expression levels of the CDC6 deletion 
mutant (Figure 113).  This result further confirms that the effect of mitomycin 




Figure 111.  CDC6 degradation upon mitomycin C treatment is not mediated 
by APC
Cdh1
.  HEK293 cells were transfected with 20 nM control siRNA or 
Cdh1 siRNA for 3 days followed by mitomycin C (10 μg/μl) or MLN4924 (1 















Figure 112. Location of D box and KEN box in CDC6 protein.  D box 
(RXXLXXXXN) is highlighted in yellow and KEN box (KEN) is highlighted 
in turquoise.  Vertical line indicates area that is removed in the CDC6-V5 D 




Figure 113.  CDC6 degradation upon mitomycin C treatment is not mediated 
by APC
Cdh1
.  HEK293 cells were transfected with wild type CDC6-V5 (0.4 μg) 
or CDC6-V5 D and KEN box deletion mutant (0.4 μg) for 3 days followed by 
treatment with MG-132 (20 μM), MLN4924 (3 μM) or mitomycin C (10 μg/μl) 








5.2.6 CDC6 degradation upon mitomycin C treatment is not mediated by 
a Cullin RING E3 Ligase but is dependent on the neddylation pathway 
 
To test the involvement of Cullin RING E3 ligases in the mitomycin C 
dependent CDC6 degradation, I used MLN4924 to inhibit the activity of all 
Cullin E3 ligases.  Interestingly, MLN4924 treatment prevented CDC6 protein 
degradation upon mitomycin C treatment (Figures 114).  These results 
suggested that Cullin E3 ligases may play a role in mediating the effect of 
mitomycin C on CDC6 stability.  To further confirm the effect of MLN4924 
on CDC6 stability upon mitomycin C treatment, I used a tetracycline inducible 
form of the dominant negative (C111S mutant) Ubc12 (Chew et al., 2007).  
The dnUbc12 cells have a defective neddylation system and therefore inactive 
Cullin E3 ligases.  Induction of dnub12 expression also prevented the 









Figure 114.   CDC6 degradation upon mitomycin C treatment is dependent on 
the Nedd8 pathway.  HEK293 cells were treated with mitomycin C (10 μg/μl) 








Figure 115.   CDC6 
degradation upon 
mitomycin C treatment is 
dependent on the Nedd8 
pathway.  HEK293 cells 
were transfected with 0.4 μg 
dnUbc12-HA pcDNA3 or 
pcDNA3 vector control for 
3 days followed by addition 
of mitomycin C (10 μg/μl) 
for 8 hours and cell lysis.   
 
 
Next, I wanted to identify which member of the Cullin E3 ligase 
family is involved in the mitomycin C mediated CDC6 degradation.  To this 
end, dominant negative mutant forms of the different members of the Cullin 
E3 ligase family were used.  Dominant-negative cullin proteins contain only 
the N-terminal portion of the respective cullin proteins.  They are able to bind 
to substrate receptor subunits and substrate, but are unable to interact with the 
RING domain protein Rbx1.  Dominant-negative cullins therefore lack E3 
ubiquitin ligase activity.  They are widely used to block the function of 
specific Cullin E3 ubiquitin ligases and to validate substrate proteins.  I 
validated dnCul1 by confirming increased expression levels of the known 
Cul1 substrate p27 (Figure 116).  In contrast, no increase in CDC6 protein 
levels was observed upon induction of dnCul1 (Figure 116).  This indicates 
that Cul1 E3 ligases are not responsible for the mitomycin C mediated CDC6 
ubiquitination and degradation.  Similarly, induction of dominant negative 
Cul3 (dnCul3-V5, amino acids 1-427) in a HEK293 cell line stably expressing 





treatment (Figure 117).  This shows that Cul3 does not mediate mitomycin C 
induced CDC6 degradation.   
 
Figure 116.   CDC6 degradation 
upon mitomycin C treatment is 
independent of Cul1 E3 Ligase.  
HEK293 cells were transfected 
with dnCul1-V5 pcDNA3 (1 μg) 
or pcDNA3 vector control (1 μg) 
for 3 days followed by mitomycin 
C (10 μg/μl) treatment for 8 hours 






Figure 117.   CDC6 
degradation upon mitomycin C 
treatment is independent of Cul3 
E3 Ligase.  HEK293 cells stably 
expressing dnCu3-V5 were 
induced with 1 μg/μl 
tetracycline for 24 hours 
followed by mitomycin C (10 
μg/μl) treatment for 8 hours and 
cell lysis.  
 
There are two mammalian Cul4 isoforms, Cul4a and Cul4b, which are 
known to share extensive sequence homology and possibly functional 
redundancy.  Hence, to test if Cul4 is involved, overexpression of dnCul4a-V5 
(amino acids 1 to 439) and dnCul4b-FLAG (amino acids 1-594) individually 
(Figure 118) or co-expression of the two Cul4 isoforms (Figure 119) were 
performed in HEK293 cells.  Overexpression of dnCul4a and/or dnCul4b had 
no significant effect on mitomycin C induced CDC6 protein degradation, thus 
indicating that CDC6 is not a substrate of Cul4 during mitomycin C dependent 













Figure 118.   CDC6 degradation upon mitomycin C treatment independent of 
Cul4a and Cul4b E3 Ligases.  HEK293 cells transfected with 0.4 μg pcDNA3 
vector control, dnCul4a-V5 or dnCul4b-FLAG for 3 days were treated with 10 
μg/μl mitomycin C for 8 hours before cell lysis.  
 
 
Figure 119.   CDC6 degradation 
upon mitomycin C treatment is 
independent of Cul4a and Cul4b 
E3 Ligases.  HEK293 cells were 
transfected with pcDNA3 vector 
control (0.6 μg) as control or co-
transfected with dnCul4a-V5 (0.3 
μg) and dnCul4b-FLAG (0.3 μg) 
for 3 days followed by mitomycin 
C (10 μg/μl) treatment for 8 hours 
and cell lysis. 
 
 
Because dnCul2 and dnCul5 are expressed at much lower levels 
compared to dominant-negative forms of other cullins (Chew and Hagen, 
2007), I used an alternative approach to inhibit Cul2 and Cul5 based E3 
ligases.  Both Cul2 and Cul5 utilize Elongin B/C as an adaptor to recruit 
substrate receptors.  Hence, to test for involvement of Cul2 and Cul5, siRNA 
mediated silencing of Elongin C was performed.  I first validated the 






Cul2 substrate HIF-1.  As expected, with the knock down of Elongin C, HIF-
1 protein was stabilized (Figure 120).  To further confirm this, HEK293 cells 
were incubated at 1 % O2 to stabilize HIF-1 protein followed by 
reoxygenation to induce the degradation of the HIF-1 protein.  As can be 
observed in Figure 121, in cells transfected with control siRNAs, HIF-1 
protein is stable in hypoxia and rapidly (within 7 min) degraded upon 
reoxygenation.  However, with Elongin C knockdown, HIF-1 degradation 
was markedly delayed upon reoxygenation (Figure 121).  To determine the 
involvement of Cul2 and Cul5 in CDC6 regulation, I next tested if Elongin C 
knockdown affects CDC6 stability.  No effect on CDC6 stability was observed 
with Elongin C knock down in cells treated with mitomycin C (Figure 122).  
This indicates that Cul2 and Cul5 do not regulate CDC6 protein stability upon 
mitomycin C treatment.   
 
Figure 120.   siRNA mediated silencing of 
Elongin C stabilizes HIF1.  HEK293 cells 
were transfected with 20 nM control or 
Elongin C siRNAs for 3 days before cell 













Figure 121. siRNA mediated silencing of Elongin C stabilizes HIF1.  
HEK293 cells transfected with 20 nM control or Elongin C siRNAs for 3 days 
were incubated at 1 % O2 for 4 hours followed by cell lysis immediately or 7 








Figure 122.   CDC6 degradation 
upon mitomycin C treatment is not 
mediated by Cul2 and Cul5 E3 
Ligases.  HEK293 transfected with 
20 nM control or Elongin C 
siRNAs for 3 days were treated 
with mitomycin C (10 μg/μl) for 8 
hours before cell lysis.   
 
 
My results suggest that none of the well characterized Cullin E3 
ligases regulates CDC6 stability upon mitomycin C treatment.  To confirm 
these results, I utilized an alternative approach.  Hence, to test the involvement 
of Cullin E3 ligases directly, siRNA mediated silencing of Rbx1, a subunit of 
all Cullin E3 ligases, was carried out.  The reported Cullin E3 ligase substrates 
HIF-1 and SLBP were stabilized with Rbx1 silencing (Figure 123).  It has 
been reported that HIF-1 protein synthesis is inhibited by mitomycin C 
treatment (Lou et al., 2010), hence explaining the reduced HIF-1 protein 
levels in the presence of the DNA damaging agent in both control and Rbx1 
knockdown cells (Figure 123).  Knockdown of Rbx1 also increased the basal 
CDC6 protein concentration.  This is likely secondary to effects of Cullin E3 
ligase inhibition on cell cycle progression, as described above.  Knockdown of 
Rbx1 did not affect CDC6 stability when cells were treated with mitomycin C 
(Figure 123).  This result indicates that mitomycin C induced CDC6 






Figure 123.   CDC6 
degradation upon 
mitomycin C 
treatment is not 
mediated by Cullin E3 
Ligases. HEK293 
cells were transfected 
with 20 nM control or 
Rbx1 siRNAs for 3 
days followed by 
mitomycin C (10 
μg/μl) treatment for 8 
hours and cell lysis.   
 
 
Inhibition of the neddylation pathway with MLN4924 treatment or 
induction of dnUbc12 expression blocks CDC6 degradation.  This indicates 
that the Nedd8 pathway is involved in the mitomycin C induced CDC6 protein 
degradation. However, the effect of inhibiting the Nedd8 pathway is 
independent of Cullin E3 ligases. These results suggest that the Nedd8 
pathway mediates mitomycin C induced CDC6 degradation via an alternative 
target.   It has been reported that the MDM2 RING E3 ubiquitin ligase 
promotes Nedd8 modification of the p53 tumor suppressor protein as well as 
its own neddylation. This function is independent of Cullin E3 ligase activity 
(Xirodimas et al., 2004).  Hence, I next tested if MDM2 regulates CDC6 
stability in the presence of mitomycin C.  As can be observed, overexpression 
of MDM2 did not have any significant effect on CDC6 levels upon mitomycin 
C treatment (Figure 124).  This indicates that MDM2 does not mediate the 
mitomycin C induced CDC6 degradation.  My results suggest that neddylation 





to characterize the mechanisms through which neddylation affects CDC6 
stability upon DNA damage. 
 
Figure 124.   CDC6 degradation upon mitomycin C treatment is not mediated 
by MDM2.  HEK293 cells were transfected with 0.4 μg pcDNA3 vector 
control or MDM2 for 3 days before treatment with mitomycin C (10 μg/μl) for 







CDC6 is an essential regulator of DNA replication in eukaryotic cells 
and its timely degradation is important for normal cell cycle progression.  In 
addition, DNA damage induced CDC6 degradation is likely to play an 
important role to prevent rereplication and block cell cycle progression by 
promoting DNA damage checkpoint functions.  A major pathway through 
which CDC6 protein stability is regulated is via cell cycle dependent 
ubiquitination by the APC
Cdh1
 E3 ubiquitin ligase.  In this study, I 
characterized potential alternative mechanisms that regulate CDC6 protein 
stability.  Cullin E3 ligases are an important class of cellular E3 ubiquitin 
ligases that have been implicated in CDC6 ubiquitination in budding and 
fission yeast.  Cullin E3 ligases have also been suggested to play a role in 
mediating CDC6 degradation in mammalian cells.  Here I demonstrate that 
although MLN4924, which inhibits all Cullin E3 ligases, led to marked CDC6 
accumulation, CDC6 stability is not regulated by Cullin E3 ligases.  The effect 
of the Cullin E3 ligase inhibitor is a consequence of a delay in cell cycle 
progression whereby the majority of the MLN4924 treated cells were arrested 
in G1 phase.  
 
To study DNA damage induced CDC6 degradation, I used the DNA 
crosslinking agent mitomycin C.  This drug exerted a pronounced inhibitory 
effect on cellular CDC6 protein levels.  It has been reported that DNA damage 
induced by UV irradiation and MMS leads to CDC6 ubiquitination and 




Notably, I found that the effect of mitomycin C on CDC6 is not mediated by 
the HUWE1 E3 ligase, indicating that there are other ubiquitin ligases that 
regulate CDC6 stability.  Furthermore, I also observed that the known CDC6 
regulator APC
Cdh1
 does not mediate CDC6 ubiquitination and degradation 
upon mitomycin C treatment.  Interestingly, treatment of cells with MLN4924 
or induction of dnUbc12 expression prevents the CDC6 downregulation by 
mitomycin C.  This indicates that a functional Nedd8 pathway is required for 
mitomycin C induced CDC6 degradation.  The best characterized targets of 
the Nedd8 pathway are Cullin E3 ligases.  However, my studies indicate that 
Cullin E3 ligases are not involved in mitomycin C induced CDC6 degradation. 
Thus, inhibition of Cullin E3 ligases using different approaches was without 
effect on CDC6 protein stability in mitomycin C treated cells.  Hence, my 
results suggest that CDC6 stability in response to mitomycin C is regulated by 
a neddylation dependent mechanism that does not involve Cullin E3 ligases.  
This suggests that Nedd8 can also exert important cellular effects in a Cullin 
independent manner.  In line with this, Cullin independent, RNF111 E3 
ubiquitin ligase dependent neddylation has recently been reported to play an 
important role in the DNA damage response (Ma et al., 2013). 
 
In conclusion, my studies provide novel insight into the mechanisms 
underlying ubiquitin dependent regulation of CDC6 protein stability.  My 
results indicate that contrary to budding and fission yeast, Cullin E3 ligases 
are not involved in CDC6 degradation during the normal cell cycle in 
mammalian cells.  It is likely that in mammalian cells APC
Cdh1
 is the exclusive 




induces an alternative mechanism of CDC6 degradation including a novel 
pathway that involves a Nedd8 dependent but Cullin E3 ligase independent 
degradation pathway.  My results provide evidence that the neddylation 





6.0 Conclusions and future studies  
 
 My project aimed to characterize the different mechanisms through 
which cells respond to hypoxic stress.  The cellular response to hypoxic stress 
is complicated and various different mechanisms are activated in response to 
low oxygen concentrations.  My thesis focused on how the mTORC1 pathway 
is regulated through changes in oxygen concentrations.  I also studied the post-
translational regulation of the important hypoxia-induced regulator of the 
mTORC1 pathway REDD1 as well as of the key player of replication in the 
cell cycle CDC6. 
 
Changes in oxygen concentrations regulate mTORC1 activity in a 
highly dynamic manner whereby the inhibition of mTORC1 in hypoxia is 
rapidly reversed upon reoxygenation.  My results show that the rapid response 
of mTORC1 to changes in oxygen concentrations is not mediated by the HIF 
transcription factor or its transcriptional targets REDD1 and BNIP3.  
Furthermore, I also show that mTORC1 inhibition in hypoxia is independent 
of transcription and new protein synthesis, suggesting a post-translational 
regulation of mTORC1 activity in response to changes in oxygen 
concentrations.  Lastly, my results indicate that hypoxia regulates mTORC1 
directly at the level of mTORC1 and my preliminary results showed that this 
may involve a heme containing protein.  In future studies, it would be 
interesting to identify the heme containing protein that regulates mTORC1 





 REDD1 is a negative regulator of mTORC1 in hypoxia that is highly 
unstable with a very short half-life.  In my study to characterize the post-
translational regulation of REDD1, I have identified that mTORC1 regulates 
REDD1 protein stability in a mTORC1-REDD1 feedback loop manner.  
Contrary to a previous study, my results indicated that REDD1 is not 
ubiquitinated by Cul4a or other Cullin RING E3 ubiquitin ligases.  
Furthermore, the ubiquitination and degradation of REDD1 is not dependent 
on phosphorylation by GSK3β.  Although the silencing of HUWE1 E3 
ubiquitin ligase led to increased REDD1 protein levels, HUWE1 does not 
regulate REDD1 protein stability.  Hence, the E3 ligase that mediates REDD1 
ubiquitination is currently still unknown and its identification would be an 
important task.   
 
 
 CDC6 is a key regulator of DNA replication in the cell cycle as it is an 
essential component of the preRC.  We initially hypothesized that the CDC6 
protein is regulated in an oxygen dependent manner.  However, my studies 
indicate that the CDC6 protein level is not affected by hypoxia.  Hence, I 
characterized the post-translational regulation of CDC6 in normoxia.  In my 
study, I found that in contrast to reports of CDC6 regulation by Cullin E3 
ligases in budding and fission yeast, regulation of CDC6 stability in 
mammalian cells is independent of Cullin E3 ligases.  Stabilization of CDC6 
protein upon inhibition of Cullin E3 ligases is a secondary consequence of a 
delay in cell cycle progression.  Furthermore, the treatment of cells with the 
DNA damage inducing agent mitomycin C induced CDC6 degradation 




APC.  Instead, an alternative mechanism involving a Nedd8 dependent, Cullin 
E3 ligases independent degradation pathway is involved.  It will be very 
interesting to characterize this novel mechanism in future work. 
 
 In all three parts of my project, I did not find out the exact mechanisms 
involved.  With regards to the identification of the molecular mechanism of 
mTORC1 regulation in hypoxia, I used multiple candidate approaches as well 
as a candidate siRNA screen approach.  In future studies, it would likely be 
necessary to devise non-biased, genetic cellular screening methods to obtain 
more detailed insights.  With regards to the mechanism of REDD1 and CDC6 
ubiquitinations, the identification of E3 ubiquitin ligases for ubiquitin-
proteasome substrates is notoriously difficult and non-biased biochemical or 
siRNA based approaches would be necessary in future work.  In my work, I 
have, however, eliminated a number of possible mechanisms or pathways that 
were reported to or could potentially regulate the mTORC1 pathway or 
REDD1 and CDC6 protein stability.  These results are likely to greatly 
promote and help in the design of future mechanistic studies to characterize 
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